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Résumé 
Le virus de l’hépatite C (VHC) est un problème mondial. La majorité des personnes 
infectées (70-85%) développent une infection chronique qui cause des complications 
hépatiques. Le seul régime thérapeutique approuvé pour le VHC est l'interféron alpha (IFN-
α). Ce traitement a un taux de réussite de 50-80% selon le génotype de virus et le moment 
de l'initiation de la thérapie. Les facteurs régissant la réponse au traitement ne sont pas bien 
définis. Des études antérieures ont suggéré un rôle potentiel de la réponse immunitaire de 
l'hôte au succès de la thérapie, toutefois, ces résultats sont controversés.  
Nous avons émis l'hypothèse que la réponse immunitaire de l’hôte sera plus efficace 
chez les patients qui commencent la thérapie tôt pendant la phase aiguë de l'infection. En 
revanche, la réponse immunitaire sera épuisée lorsque le traitement est initié pendant la 
phase chronique. L'objectif principal de ce mémoire est d’étudier les facteurs 
immunologiques qui régissent la réponse à la thérapie, et de déterminer si la contribution de 
la réponse immunitaire de l'hôte peut être influencée par la période de l'infection.  
Nos résultats démontrent l'efficacité de la restauration de la réponse immunitaire 
spécifique au VHC lorsque la thérapie par l'interféron est initiée tôt. Ceci est démontré par 
le sauvetage des cellules T efficaces spécifiques au VHC efficace similaires à celles 
observées chez les individus qui ont résolu spontanément, suggérant ainsi  qu'elles jouent 
un rôle actif dans la réponse au traitement. Toutefois, cette réponse n'a pas été restaurée 
chez les patients traités au cours de la phase chronique. Ces résultats ont des implications 
importantes dans la compréhension des mécanismes sous-jacents à la réponse aux 
traitements actuels et au développement des nouvelles thérapies. 
 
Mots-clés : virus de l’hépatite C (VHC), l'interféron alpha (IFN-α), immunité adaptative, 
infection aiguë, infection chronique. 
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Abstract 
Hepatitis C virus (HCV) is a major public health problem worldwide.  Only 15-30% 
of infected individuals clear the virus spontaneously, while the majority develops chronic 
infection that causes liver complications. The only approved therapy for HCV is interferon 
alpha (IFN-α) based. This therapy has a 50-80% success rate depending on the infecting 
virus genotype and the timing of initiation of therapy. Factors governing the response to 
therapy are not well defined.  Previous studies have suggested a role for the host immune 
response in the success of therapy. However, these results were controversial.   
We hypothesized that host immunity has an effective role in the success of IFN-α 
therapy when initiated early during the acute phase of HCV infection, while late initiation 
during the chronic phase minimizes this role. The main objective of this thesis was to 
dissect the immunological factors governing the differential response to IFN-α therapy, and 
to determine if the contribution of the immune response to success of therapy might be 
influenced by the period of infection.   
Our results demonstrate restoration of efficient HCV-specific immune responses 
when therapy is initiated early during the acute phase. This is demonstrated by the rescue of 
functional HCV-specific T cells similar to those observed in spontaneously resolved 
individuals, suggesting that they may play an active role in response to therapy. However, 
such responses were not restored following late therapy suggesting irreversible damage to 
the host’s defence system with chronicity. These findings have important implications in 
understanding the mechanisms underlying response to current treatments and development 
of novel therapies.  
 
Keywords: Hepatitis C virus (HCV), Interferon alpha (IFN-α), adaptive immunity, acute 
infection, chronic infection. 
  
v 
 
Table of contents 
Résumé ..................................................................................................................................iii 
Abstract ................................................................................................................................. iv 
Table of contents .................................................................................................................... v 
List of tables .......................................................................................................................... ix 
List of figures ......................................................................................................................... x 
List of abbreviations ..............................................................................................................xi 
Dedication ...........................................................................................................................xiv 
Acknowledgments ................................................................................................................ xv 
Chapter 1: Literature Review ................................................................................................. 1 
1.1. Historical preface ........................................................................................................ 2 
1.2. The virus...................................................................................................................... 2 
1.2.1. General characteristics and structure.................................................................... 2 
1.2.2. HCV genome and proteins ................................................................................... 3 
1.2.2.1. The non-coding regions (NCRs) ................................................................... 5 
1.2.2.2. The viral proteins........................................................................................... 5 
1.2.3. Classification ........................................................................................................ 6 
1.2.4. Difficulties in studying HCV ............................................................................... 7 
1.2.5. HCV life cycle...................................................................................................... 8 
1.2.5.1. Receptors and viral entry............................................................................... 9 
1.2.5.2. Translation, replication and virion release .................................................. 11 
1.3. The disease ................................................................................................................ 12 
1.3.1. Epidemiology ..................................................................................................... 12 
1.3.2. Transmission ...................................................................................................... 13 
1.3.3. Natural history of HCV infection ....................................................................... 14 
1.4. The immune system and HCV .................................................................................. 16 
1.4.1. Innate immunity ................................................................................................. 17 
1.4.2. Adaptive immunity............................................................................................. 19 
  
vi 
 
1.4.2.1. Humoral immunity ...................................................................................... 19 
1.4.2.2. Cell Mediated Immunity (CMI) .................................................................. 20 
1.4.2.2.1. CD4+ T cells in HCV infection............................................................ 20 
1.4.2.2.2. CD8+ T cells in HCV infection............................................................ 21 
1.4.2.2.3. Memory CMI and recurrent infection .................................................. 22 
1.4.3. Failure of the immune response against HCV.................................................... 23 
1.4.3.1. Primary failure of the HCV-specific immune response .............................. 23 
1.4.3.2. Viral evasion strategies ............................................................................... 27 
1.5. HCV treatment .......................................................................................................... 29 
1.5.1. Treatment regimens............................................................................................ 29 
1.5.2. Patterns of response to therapy........................................................................... 30 
1.5.3. Factors affecting response to therapy................................................................. 31 
1. 5.4. Mechanisms of action of therapy ...................................................................... 32 
1.5.5. Novel therapies and vaccine trials...................................................................... 32 
1.5.6. Role of the immune system in the response to therapy...................................... 33 
1.6. Hypothesis and objectives ......................................................................................... 35 
Chapter 2: Articles................................................................................................................ 38 
Article 2.1. ........................................................................................................................ 39 
2.1.1. Abstract .............................................................................................................. 41 
2.1.2. Introduction ........................................................................................................ 42 
2.1.3. Materials and Methods ....................................................................................... 45 
2.1.3.1. Study subjects and clinical follow-up ......................................................... 45 
2.1.3.2. HCV RNA testing and quantification ......................................................... 46 
2.1.3.3. Peptides and peptide-HLA class I tetramers. .............................................. 47 
2.1.3.4. Flow-cytometry antibodies and reagents..................................................... 47 
2.1.3.5. Multiparametric phenotypic characterization of HCV-specific T cells. ..... 48 
2.1.3.6. Intracellular cytokine staining (ICS) and CD107a degranulation assay. .... 49 
2.1.3.7. CFSE proliferation assays ........................................................................... 49 
  
vii 
 
2.1.3.8. Cell sorting experiments.............................................................................. 49 
2.1.3.9. HCV epitope sequencing............................................................................. 50 
2.1.4. Results ................................................................................................................ 51 
2.1.4.1. Identification of acute HCV and longitudinal phenotypic analysis of HCV-
specific CD8+ T cells. .............................................................................................. 51 
2.1.4.2. Spontaneously resolved HCV infection is associated with the early 
development of poly-functional T cells.................................................................... 52 
2.1.4.3. Acute HCV with chronic evolution is associated with diminished function 
and rapid loss of HCV-specific T cells..................................................................... 54 
2.1.4.4. CD127 distinguishes a unique poly-functional, memory T cell population 54 
2.1.4.5. Early therapeutic intervention rescues poly-functional long-lived memory T 
cells........................................................................................................................... 55 
2.1.4.6. Transient restoration of HCV-specific immune responses during therapy 
followed by loss upon viral recurrence. ................................................................... 57 
2.1.4.7. Phenotypic and functional changes observed are not due to changes in 
targeted epitopes. ...................................................................................................... 58 
2.1.5. Discussion .......................................................................................................... 60 
2.1.6. Acknowledgements ............................................................................................ 65 
2.1.7. Figures ................................................................................................................ 66 
2.1.8. Figure Legends ................................................................................................... 76 
2.1.9. Tables ................................................................................................................. 82 
2.1.10. References ........................................................................................................ 85 
Article 2.2. ........................................................................................................................ 95 
2.2.1. Abstract .............................................................................................................. 97 
2.2.2. Introduction ........................................................................................................ 98 
2.2.3. Methods, Results and Discussion....................................................................... 99 
2.2.4. Acknowledgements .......................................................................................... 104 
2.2.5. Figures .............................................................................................................. 105 
  
viii 
 
2.2.6. Figure Legends ................................................................................................. 110 
2.2.7. Tables ............................................................................................................... 112 
2.2.8. References ........................................................................................................ 114 
Chapter 3: Discussion......................................................................................................... 118 
3.1. Successful HCV-specific CD8+ T cells in spontaneously resolved infections are 
poly-functional memory T cells ..................................................................................... 120 
3.2. Similar profile of early-treatment induced memory T cells and normal memory T 
cells................................................................................................................................. 121 
3.3. Role of viral-sequence variation in memory T-cell preservation............................ 124 
Conclusion.......................................................................................................................... 127 
Perspectives ........................................................................................................................ 128 
Bibliography....................................................................................................................... 129 
Appendix I: The candidate’s contribution to the articles ........................................................I 
 
  
ix 
 
List of tables 
Chapter 2 
Article 2.1. 
Table 1. ............................................................................................................................... 82 
Table 2. ............................................................................................................................... 82 
Table 3. ............................................................................................................................... 83 
Supplementary Table 1. .................................................................................................... 84 
 
Article 2.2. 
Supplementary Table 1. .................................................................................................. 112 
Supplementary Table 2. .................................................................................................. 113 
 
  
x 
 
List of figures 
Chapter 1 
Figure 1.1 HCV genomic organization and encoded proteins............................................... 4 
Figure 1.2 A schematic diagram of HCV’s replication cycle................................................ 8 
Figure 1.3 Early steps of HCV’s replication cycle.............................................................. 10 
Figure 1.4 Prevalence of HCV infection worldwide ........................................................... 12 
Figure 1.5 Major events in the immune response against HCV.......................................... 16 
Figure 1.6 Successful versus unsuccessful CMI response during acute HCV infection..... 26 
Chapter 2 
Article 2.1. 
Figure 1. .............................................................................................................................. 66 
Figure 2. .............................................................................................................................. 67 
Figure 3. .............................................................................................................................. 68 
Figure 4. .............................................................................................................................. 69 
Figure 5. .............................................................................................................................. 70 
Figure 6. .............................................................................................................................. 71 
Figure 7. .............................................................................................................................. 72 
Supplementary Figure 1. .................................................................................................. 73 
Supplementary Figure 2. .................................................................................................. 74 
Supplementary Figure 3. .................................................................................................. 75 
Article 2.1. 
Figure 1. ............................................................................................................................ 105 
Figure 2. ............................................................................................................................ 106 
Figure 3. ............................................................................................................................ 107 
Figure 4. ............................................................................................................................ 108 
Supplementary Figure 1. ................................................................................................ 109 
  
xi 
 
List of abbreviations 
APC   Antigen presenting cell 
ARFP   Alternative reading frame protein  
CCR   Chemokine receptor 
CFSE   Carboxyfluorescein succinimidyl ester 
CLDN1  Claudin-1 
CMI   Cell-mediated immunity 
CTL   Cytotoxic T lymphocytes 
CTLA-4  Cytotoxic T lymphocyte associated antigen-4 
DC   Dendritic cell 
dsRNA  Double-stranded RNA 
E1-E2   Envelope glycoprotein 1- Envelope glycoprotein 2 
eIF   Eukaryotic initiation factor 
ELISpot  Enzyme-linked immuno spot 
EVC   Early virological clearance 
EVR   Early virological response 
F protein  Frameshift protein 
FasL   Fas ligand 
FOXP3  Forkhead transcription factor 3 
GTP   Guanosine triphosphate 
HCC   Hepatocellular carcinoma 
HCV   Hepatitis C virus 
HCVpp  Hepatitis C virus pseudoparticles 
HLA   Human leukocyte antigen 
HVR1   Hypervariable region-1 
ICTV   International committee for the taxonomy of viruses 
IDU   Intravenous drug user 
IFN   Interferon 
  
xii 
 
IL   Interleukin 
IMPDH  Inosine-monophosphate dehydrogenase 
IP-10   Interferon-inducible protein-10 
IRES   Internal ribosome binding site 
ISG   Interferon stimulated genes 
IU   International unit 
JFH1   Japanese fulminant hepatitis 1 
Kb   Kilo bases 
KIR   Killer cell immunoglobulin-like receptors 
MAP   Multi-analyte profiling 
mDC   Myeloid dendritic cell 
Met   Methionine 
MHC-I,II  Major histocompitability complex class I, class II 
nAb   Neutralizing antibody 
NANB   Non-A non-B 
nm   Nanometre 
NCR   Non-coding region 
NK   Natural Killer 
NR   Non-responder 
NS   Non-structural 
OAS   Oligoadenylate synthetase 
OCLN   Occludin 
ORF   Open reading frame 
PAMP   Pathogen associated molecular pattern 
PBMCs  Peripheral blood mononuclear cells 
PD-1   Programmed death 1 
pDC   Plasmacytoid dendritic cell 
PEG   Polyethylene glycol 
  
xiii 
 
RdRp   RNA-dependant RNA-polymerase 
RIG-I   Retinoic-acid-inducible gene I  
RNAi   RNA interference 
SCID   Severe combined immunodeficiency  
shRNA  Short hairpin RNA  
siRNA   Short interfering RNA  
SR-BI   Scavenger receptor class B type I 
+SS RNA  Positive single-stranded RNA 
SVR   Sustained virological response 
t1/2    Half-life 
TCM   Central memory T cells 
TEM   Effector memory T cells 
Th1,2   Helper T-cell subtype 1, 2  
TJ   Tight junction   
TLR   Toll-like receptor 
TNF   Tumour necrosis factor 
Treg   Regulatory T cell 
TTEM   Transitional effector memory T cells 
tRNA   Transfer RNA 
uPA   Urokinase-type plasminogen activator 
US   United States  
UTR   Un-translated region 
WHO   World Health Organization 
    
  
  
xiv 
 
To the three most important ladies in my life;                                     
my mother, who taught me how to be a real man,                                                                 
my grandmother, who inspired my love for knowledge,                                                                               
and my wife, who supported me through the most challenging of times.    
Dédicace  
  
  
xv 
 
 Acknowledgments 
I like to think of this manuscript more as a huge human piece of work where every 
person in my life contributed a page, a phrase, or even a word, rather than being an 
individual intellectual production. I would like to express my deepest gratitude to all those 
who shared in the production of this manuscript so that my work sees the light, not only 
directly in the scientific field, but those who shared in shaping my life as a human being. 
First of all I would like to thank Dr. Naglaa Shoukry who believed in my potentials as a 
researcher and taught me many of the things I know now about research. I hope I fulfilled 
my promise of not letting you down and making you proud that I am your student. I would 
like to thank all members of my laboratory; you were my family when I had no family here 
in Montréal, and I learned something from each and every one of you. I would like to 
specifically thank Gamal Badr, Nathalie Bédard, Sandy Pelletier & Anna Tomyzck. I 
would like to acknowledge the sincere help of Dr. Nathalie Grandvaux and all members of 
her laboratory, especially Karin Fink. I would also like to thank the members of other 
laboratories in the CR-CHUM – St. Luc; especially Mohamed El-Far & Malek Jundi. I 
would like to thank all members of the Egyptian Cultural Bureau in Montréal; especially 
Dr. Nebal El-Tanbouly, Dr. Amany Fouad & Eng. Mustafa Shekib. I would like to convey 
all my respects to every professor who taught me something useful since my early years in 
education, especially Dr. Abdel-Gawwad Hashem; you are my inspiration as a professor. 
Last but not least I would like to thank each and every member of my family in 
Egypt, who had to make extra efforts during my absence. Despite the space restrictions that 
prohibit mentioning them by name, I would like to give a specific “I owe you so much” to 
Mama Somaia, Nanna Thorayya, U. Mustapha, U. Sameh, my two sisters Shaza and Shadw 
and their husbands Ehab and Kamal, Ahmed Sameh, Israa. My second family; Baba 
Mansour, Mama Randa, Godda, Reham (who pushed and helped me to finish the 
manuscript) and the special contribution of Mallouti. My friends/brothers Fofa, Sheree, 
Zoeiby & Mezo. 
  
 
 
 
 
 
Chapter 1: Literature Review 
 
 
 
 
 
 
 
 
 
 
  
2 
 
1.1. Historical preface 
Hepatitis C virus (HCV) emerged as a major health problem worldwide since the 
seventies when it was recognized as a causative agent of transfusion–associated liver 
inflammation (hepatitis) other than hepatitis A and B viruses, leading to its primary 
classification as non-A non-B (NANB) [1, 2]. It was characterized as a small enveloped 
virus being able to pass through 50 nanometre (nm) filters and inactivated by lipid solvents 
[3, 4]. In 1989 a team led by Michael Hughton at Chiron corporation cloned the genome of 
HCV from a large volume of plasma obtained from a chronically infected chimpanzee [5]. 
They demonstrated that it was a positive single stranded RNA (+ssRNA) molecule, nearly 
10,000 nucleotides long [6]. The earliest epidemiological studies reported that over 130 
million people worldwide were infected with this newly discovered virus [7].  
1.2. The virus 
1.2.1. General characteristics and structure  
HCV is a non-cytopathic virus primarily infecting hepatocytes [8], yet the high rate 
of extra-hepatic manifestations accompanying HCV infection suggested that peripheral 
blood mononuclear cells (PBMCs) were infected. It is already reported that B cells, T cells 
and dendritic cells contained HCV RNA [9]. 
Despite the huge advances in the study of the HCV genome and proteins, viral 
particles have only been extensively studied through culture systems since 2005 [10]. Early 
data form electron microscopy and imaging demonstrated that the HCV nucleocapsid is 
approximately 40-70 nm in size and built from units of Core protein together with the RNA 
genome surrounded by a human-cell derived membrane with embedded envelope 
glycoproteins (E1/E2) heterodimers [10, 11].   
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1.2.2. HCV genome and proteins 
The HCV genome is an uncapped +ssRNA of approximately 9.6 kilo bases (kb) 
[11]. It contains an uninterrupted open reading frame (ORF) encoding a polyprotein 
precursor of approximately 3000 amino acids [5] which is further processed by cellular and 
viral proteases into ten proteins: four structural proteins (Core, E1, E2, p7) and six non–
structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) (Fig. 1.1.), all of which are 
transmembrane proteins associated with intracellular membranes [12]. The genome also 
contains a 5’untranslated region (5’UTR) and a 3’UTR [13]. An alternate reading frame 
protein (ARFP), also known as frameshift protein (F protein), was identified in the HCV 
Core region due to a ribosomal frame-shift [14]. Yet, it is not required for HCV replication 
[15] and its function(s) remain to be elucidated.  
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Figure 1.1: HCV genomic organization and encoded proteins. HCV RNA is translated 
into a single polyprotein molecule which is further processed into the HCV proteins and 
enzymes. The scissors show the early processing steps that take place by cellular enzymes, 
followed by auto-processing by the virus’s own enzymes shown by arrows. 
(Adapted from Moradpour DF, et al., Nat. Rev. Microbiol., 2007) [12] 
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1.2.2.1. The non-coding regions (NCRs) 
Most of the 5’UTR is occupied by the internal ribosome binding site (IRES) that 
can direct translation of the downstream reading frame in a cap independent manner [16-
18]. It forms 4 domains (I-IV), domains I and II are essential for HCV RNA replication 
[19]. 5’UTRs from different genotypes direct translation with different efficiencies [20, 21]. 
The 3’UTR is formed of a short variable region of approximately 30 nucleotides, a poly 
(U/UC) stretch and a highly conserved 98-base sequence designated the ‘x-tail’ [22, 23]. 
Current evidence suggest the importance of 3’UTR in viral replication [24]   
1.2.2.2. The viral proteins 
The Core protein amino acid sequence is highly conserved among different HCV 
strains [25]. The Core is involved in the formation of the HCV nucleocapsid [12] and was 
shown to modulate the host’s intracellular signalling pathways [26]. The two envelope 
glycoproteins (E1 and E2) form complexes which are the building unit of the envelope 
[27], and are necessary for viral entry [28, 29]. The P7 protein is a small hydrophobic 
polypeptide suggested by many reports to function as a viroporin or ion channel [30, 31].  
NS2 is essential for viral replication in vivo [32]. NS2/3 possesses a cysteine 
autoprotease activity necessary for the polyprotein processing. This activity resides in the 
C-terminal half of NS2 and the N-terminal third of NS3 [33, 34].  
NS3 is a complex multi-functional molecule essential for both viral protein 
processing and RNA replication [34], with a serine protease located in the N-terminal third 
and RNA helicase/NTPase residing in the C-terminal two thirds of the protein [35]. The 
helicase domain unwinds RNA-RNA substrates in a 3’ to 5’ direction [36]. The serine 
protease catalyses the processing of the polyprotein downstream of the NS3 region [25]. 
NS4A is the co-factor for the NS3 serine protease [37].  
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NS4B and NS5A are poorly characterized with functions not fully elucidated. 
However, studies show that NS4B induces the formation of a membranous-web 
compartment where viral replication takes place [38, 39], and cell-culture adaptive 
mutations mapped to the NS5A enhance RNA replication suggesting its importance for 
viral replication [40-42].  
NS5B is the viral RNA-dependant RNA-polymerase (RdRp) responsible for HCV-
RNA replication [12] with the hallmark GDD motif  [43] and a typical right-hand structure 
[44, 45]. As with other RNA viruses this enzyme lacks proof-reading activity and is highly 
error prone, leading to the emergence of different viral populations circulating in the blood 
of an individual patient as a ‘mosaic’ of highly related sequences termed ‘quasispecies’. 
These quasispecies despite phylogenetic proximity and limited sequence differences differ 
in replication fitness and response to therapy [46].  
1.2.3. Classification  
Given that HCV has genomic organization similar to flaviviruses [47] the 
International Committee for the Taxonomy of Viruses (ICTV) classified HCV as a member 
of the hepacivirus genus in the Flaviviridae family since 1991 [48]. Despite variability of 
the HCV genome, certain highly conserved regions were identified in the Core/E1 and 
NS5B that were used as the basis of HCV genotyping in 1994, thus classifying HCV into 
genotypes 1 to 6 which differ from each other by 31–33 % at the nucleotide level, and 
many subtypes (e.g. 1a, 1b, 1c) with 20–25 % differences [49-52]. HCV variants are 
classified based on partial sequencing of the highly conserved regions Core/E1, NS5B, 
3’UTR and 5’UTR [53], 5’UTR being the region commonly used for genotyping [54, 55]. 
Despite the sequence diversity of HCV, all genotypes have an identical set of genes of 
nearly identical size [55]. Yet, the different genotypes show marked differences in 
geographic distribution and response to therapy [56]. 
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1.2.4. Difficulties in studying HCV 
The major obstacles facing HCV research include the difficulty of early diagnosis of 
acute cases, the absence of animal models other than the chimpanzee and the inability to 
produce complete infectious virus particles in an in vitro culture system. 
Acute infection, empirically defined as the first six months after infection, is often 
undiagnosed because it is usually asymptomatic [57]. That is why most of the initial views 
about HCV were mainly based on studying chronically infected cases [46]. Studies of early 
events of acute infection relied on clinical parameters to identify patients with symptomatic 
HCV [58-60].  Recently there was a focus on prospective studies of human cohorts at high 
risk of HCV infection, as health care workers and intravenous drug users (IDU) [61].  
Different animal models were developed for studying HCV, but these supported 
limited replication of the virus (e.g. SCID/uPA mice) [62]. Chimpanzees remain the only 
available model for HCV persistence [63]. Despite the high cost, different clinical course 
and ethical limitations, this model enabled assessment of the infectivity of HCV clones and 
provided insight into the early immune events and protective immunity [64].  
The inability to produce infectious HCV particles in culture systems promoted the 
development of alternative in vitro models to study the HCV viral cycle, such as, using 
recombinant HCV envelope proteins to generate HCV pseudo-particles (HCVpp) [29, 65]. 
But these models were only useful for studying the entry steps of the viral life cycle. 
Replicon systems were the starting point for studying the virological characteristics of HCV 
and enabled the recapitulation of intracellular events of the viral cycle, but theses replicons 
were unable to produce infectious viral particles [66]. In 2005 Wakita et al. identified a 
genotype 2a HCV isolate from a Japanese patient with fulminant hepatitis (JFH-1) that 
replicated in tissue culture of a human hepatoma cell line producing high titres of infectious 
virus particles in vitro capable of infecting naïve culture cells and chimpanzees [10].  
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1.2.5. HCV life cycle 
                        
Figure 1.2: A schematic diagram of HCV’s replication cycle. The HCV replication cycle 
steps: 1- Binding to specific receptors and entry, 2- Release of the genome, 3- Translation 
and processing of the produced polyprotein, 4- Replication producing numerous genomes, 
5- Assembly of virus particles and 6- Release through the cell’s secretary pathways.  
(Adapted from Lindenbach BD and Rice CM, Nature, 2005) [67]  
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1.2.5.1. Receptors and viral entry 
Receptors involved in binding and entry of a given virus determine its tissue tropism 
and host range [25]. The first described receptors for HCV were CD81 [68] and scavenger 
receptor class B type I (SR-BI) [69], supported by the observation that antibodies or RNA 
interference (RNAi) against either CD81 or SR-BI potentially inhibit entry of HCVpp into 
hepatoma cell lines that are normally permissive [70-73]. Antibodies against CD81 do not 
affect HCVpp binding to cells, but inhibit viral entry after the initial attachment has taken 
place. Therefore it is suggested to be a co-receptor, while SR-BI is suggested to be a 
primary receptor [74, 75]. Tight junction (TJ) protein Claudin-1 (CLDN1) has also been 
identified as a receptor/co-receptor for HCV. Kinetics of inhibition suggest that the first 
encounter is with SR-BI before interacting with CD81, then CLDN1 might play a role in a 
late step (Fig. 1.3)  [76]. However, cell lines expressing all three entry factors are resistant 
to HCV entry [77], suggesting the involvement of more receptors and co-receptors. The 
most recently reported factor essential for HCV cell entry is another TJ protein, occludin 
(OCLN), which conferred HCV permissiveness to mouse cell lines [78, 79]. 
Binding is followed by fusion of the viral envelope with the cellular membrane by 
clatherin mediated endocytosis [80] then fusion with the endosomal membrane and the viral 
genome is released into the cytosol [28].  
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Figure 1.3: Early steps of HCV’s replication cycle. Sequential binding to receptors and 
co-receptors as suggested by kinetics studies, followed by clatherin dependant endocytosis, 
entry and uncoating.  
(Adapted from Moradpour DF, et al., Nat. Rev. Microbiol., 2007) [12] 
 
 
 
 
 
 
  
11 
 
1.2.5.2. Translation, replication and virion release  
Translation of the HCV genome (lacking a 5’ cap) depends on the IRES [17], which 
binds the 40s ribosomal subunit directly without the need for pre-initiation factors [81] 
forming a binary complex that binds to eukaryotic initiation factor 3 (eIF3). This nascent 
complex recruits the ternary complex of Met-tRNA-eIF2-GTP to form non-canonical 48s 
intermediate that attaches to the 60s subunit to finally give the active 80s complex forming 
the first peptide bond [82, 83]. 
The major product of HCV ORF translation is a large polyprotein that is 
subsequently processed into mature structural and non-structural proteins (Fig. 1.1). 
Junctions between structural proteins are processed by host signal peptidases from the 
endoplasmic reticulum [12, 84]. The viral non-structural (NS) proteins are processed by 
two proteases encoded by HCV RNA: the NS2/3 autoprotease that accomplishes the 
processing between NS2 and NS3 [12, 25] and the NS3/4A serine protease that processes 
the remaining four junctions by sequential cleavage [85]. 
Replication starts by the NS5B RdRp synthesis of a complementary full-length 
negative strand RNA using the genome as a template then using the negative strand for the 
production of many copies of the genomic positive strand in a replication complex [86, 87] 
associated with lipid-raft based membranes  [88, 89]. Using the reverse genetics approach, 
it has been shown that all viral enzymatic activities, the P7 gene and the 3’UTR are 
necessary for in vivo HCV-replication [32, 90, 91].  
Data from expression systems show that once an HCV nucleocapsid is formed in the 
cytoplasm it acquires an envelope as it buds through an intracellular membrane [65, 92, 93] 
producing particles of heterogeneous size ranging from 30 to 80 nm [84] that are released 
from the cell through the secretary pathway (Fig. 1.2) [25]. 
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1.3. The disease 
1.3.1. Epidemiology 
      
Figure 1.4: Prevalence of HCV infection worldwide. A world map showing the higher 
prevalence of HCV in many developing countries. The countries with the highest rate 
worldwide include Egypt, Bolivia and Mongolia.  
(Adapted from the International travel and health report, WHO, 2008) [94] 
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The World Health Organization (WHO) estimates HCV prevalence at 3.1% 
worldwide, approximately 170 million people [95]. The prevalence is higher in developing 
countries posing both a public health problem and an economic burden (Figure 1.4), the 
highest being in Egypt (15-20%) [96, 97]. Moreover, new cases occur every year, 
approximately 38,000 in the US alone [98]. In Canada, the prevalence is 0.8% with 
continuous new incidence [99]. This is equal to approximately 275,000 individuals, of 
which at least 30% are intravenous drug users (IDUs) [100]. These numbers might not be 
representative as many HCV patients belong to marginalized groups or live in secluded 
areas in developing countries with limited access to health care, where the inclusion in 
epidemiological studies is very difficult and the rate of undiagnosed infection is high [46]. 
1.3.2. Transmission 
The most efficient mode of transmission of HCV is direct exposure to infected 
blood (e.g. transfusion from infected donors, haemodialysis or injection drug usage) [101-
103].  The former was the main etiological route for the spread of HCV before its cloning 
and the implementation of blood-donor screening since the early nineties. This lead to a 
vast reduction of transfusion-related transmission [104], which now stands at less than 1% 
in developed countries [105]. Other methods of transmission are less efficient. Perinatal 
transmission takes place at an average rate of 4-7%, and only with mothers who are HCV-
RNA positive at delivery [106]. Occupational transmission [107] and  the still controversial 
sexual transmission [108, 109] account for 1.8% and 1.5%, respectively. Increased risk was 
observed with intranasal cocaine use, tattooing, body piercing, ritual scarification and 
circumcision, but still none of these activities was consistently correlated with HCV 
transmission [110, 111]. 
The high HCV prevalence in Egypt was linked to the massive anti-schistosomal 
public health program that took place during the late sixties and the early seventies. During 
this program non-disposable syringes were used with insufficient sterilization between 
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individuals, thus contributing to HCV spread. This represents a perfect example of 
iatrogenic transmission [96]. 
Presently there seem to be two patterns for HCV transmission. In developed 
countries, the sharing of contaminated needles between IDUs accounts for ~68% of new 
cases, while in the developing world unsafe therapeutic injections and transfusions account 
for ~40% [97].  
1.3.3. Natural history of HCV infection 
An important characteristic of HCV is its high tendency to establish a chronic 
infection in the host. Approximately 70% (55-85%) of acutely infected patients progress to 
chronicity [57]. Another characteristic of HCV is its rapid turnover with a half-life (t½)of 3 
hours, producing up to 10
12
 viruses in a single patient per day [112], thus reaching high 
serum titres of the virus by week one into the infection [113, 114]. Nevertheless, only one 
third of the patients develop jaundice during the acute phase of the infection [6] while the 
rest remain undiagnosed for years before any symptoms of liver disease are evident, 
thereby leading to the spread of infection and missing the opportunity of early treatment 
[115, 116]. In chronically infected patients, it was observed that levels of viraemia remain 
stable over long periods of time [117]. 
  Being a non-cytopathic virus, many studies focused on the contribution of 
immunopathogenesis to liver damage (fibrosis and cirrhosis) in HCV-infected individuals. 
Many mechanisms were proposed for immunopathogenesis, either directly due to enhanced 
CTL-mediated apoptosis of hepatocytes [118], or indirectly by persistent secretion of 
chemokines causing chronic inflammation of the liver, thus leading to tissue damage [119]. 
These studies were initially driven by the finding noting the temporal coincidence of acute 
hepatitis C symptoms –when present– with the expansion of virus-specific CTLs and the 
increase in their effector functions [120, 121]. 
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Up to 20% of patients with chronic viral hepatitis C subsequently develop 
complications including end-stage cirrhosis, liver failure and hepatocellular carcinoma 
(HCC)  [122]. These patients represent a quarter of the cirrhosis and HCC cases worldwide 
[123]. This makes hepatitis C the most common indication for orthotopic liver 
transplantation (40-50%) [124], but viral recurrence usually occurs after transplantation 
despite prophylaxis with immune globulin or other agents [125]. 
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1.4. The immune system and HCV 
     
Figure 1.5: Major events in the immune response against HCV. 1, the first cells to act 
directly against the virus are NKs. 2, NKs also induce DC maturation. 3, DCs migrate to 
the lymphoid tissue where they stimulate both CD4+ T cells to become effector Th cells 
and CD8+ T cells to become effector CTLs, 4 and 5. 6, CTLs mediate cell death by direct 
cytotoxicity, through cytokines and/or Fas/FasL mediated apoptosis. CTL, cytotoxic T 
lymphocyte ; DC, dendritic cells; FasL, Fas ligand; IFN-γ, interferon-gamma; NK, natural 
killer cells; Th, helper T cell; TNF-α, tumour necrosis factor-alpha.  
(Adapted from Kanto T and Hayashi N, Internal Medicine, 2008) [118]    
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1.4.1. Innate immunity 
Innate immunity is the first line of defence triggered by foreign pathogens including 
viruses. The initial step is recognition of molecules shared by interrelated pathogens known 
as “Pathogen Associated Molecular Patterns” (PAMPs) by cell surface or intracellular 
receptors [126]. RNA viruses are recognized by Toll-like receptors (TLRs) or nucleic acid-
binding proteins [127, 128]. In hepatocytes, pathways downstream of TLR-3 and retinoic-
acid-inducible gene I (RIG-I) are the two major signalling pathways triggered by foreign 
dsRNAs, including HCV RNA which has secondary dsRNA structures and a dsRNA 
replication intermediate [46, 129-131] culminating in the secretion of IFN-β which binds to 
the cell-surface IFN receptor initiating a positive feedback loop within infected cells [132, 
133]. This induces the expression of hundreds of type I interferon-stimulated genes (ISGs) 
in the infected cells and sends a danger signal to neighbouring uninfected cells inducing 
ISGs expression in them as well, creating a general antiviral state in the liver that limits 
HCV RNA replication and cell-to-cell spread [126, 134]. 
Induction of intracellular signalling pathways was detected as early as day two after 
HCV infection in microarray studies of liver biopsy samples obtained from HCV-infected 
chimpanzees. This activation was detected as an upregulation of ISGs in liver cells. 
However, this upregulation is detected irrespective of the final outcome of the infection, 
suggesting that most HCV isolates are resistant to the antiviral effects of this first line of 
defence [135, 136]. Nevertheless, a high level of ISGs expression was a major 
characteristic of a strong host response associated with spontaneously resolving infection, 
suggesting that the level of upregulation has an impact on HCV-outcome [137].            
As determinants of innate immunity, natural killer cells (NKs) and dendritic cells 
(DCs) are the first cells to interact with foreign pathogens non-specifically. NKs have a 
direct cytotoxic action and antiviral action through secretion of IFN-γ and tumor necrosis 
factor-alpha (TNF-α) [138], as well as having the ability to stimulate DC maturation 
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representing the link between innate and adaptive immunity (Fig. 1.5) [139]. NKs are 
constitutively inhibited from reacting against autologous-MHC class I (MHC-I) molecules 
and to be activated they have to receive activating signals surpassing the inhibitory ones 
[140-142]. This is under the control of a variety of stimulatory, co-stimulatory and 
inhibitory receptors that either bind to pathogen components or host cell ligands, one of the 
most important inhibitory receptors are members of the killer cell immunoglobulin-like 
receptors (KIRs) family [143, 144]. 
NKs are abundant in the liver and have been shown to influence the outcome of 
HCV infection [145]. One of the determinants correlating to HCV outcome being the 
threshold of NK activation which is governed by the form of the alleles of both the KIRs 
expressed on NKs and the HLA-A, -B, or -C molecules expressed on other host cells. 
Khakoo et al., reported in a large genetic study that individuals homozygous for KIR2DL3 
and HLA-C1 alleles were more likely to clear HCV infection than individuals with other 
KIR2DL:HLA-C combinations [146]. It is known that KIR2DL3 has a lower affinity for 
HLA-C1 than other KIR2DL alleles [147], so HLA-C1-mediated inhibition of NK cells is 
thought to be weaker (i.e. easier NK activation) in individuals homozygous for KIR2DL3 
and HLA-C1.  
Dendritic cells (DCs) are the most potent professional antigen presenting cells 
(APCs) able to activate naïve T cells [148]. The two major populations of DCs are the 
myeloid DCs (mDCs) and the plasmacytoid DCs (pDCs). mDCs are the major APCs 
inducing the primary T-cell response while pDCs mainly produce IFN-α thus initially 
termed interferon producing cells (IPCs) as well as amplifying the antiviral response and 
expanding memory T-cell population [149].  
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1.4.2. Adaptive immunity 
1.4.2.1. Humoral immunity 
The humoral immune response is mediated by antibodies secreted by B cells 
following their activation by helper T-cell subtype 1 (Th2) CD4+ T cells to differentiate 
into plasma cells. Humoral immunity against viral infections is effective through its ability 
to produce neutralizing antibodies (nAb) targeting surface epitopes, thus preventing viral 
binding to and/or entry into target cells [148].  
Although, HCV RNA is detectable in the serum by day two post infection [46] 
reaching high serum titres by week 1-2, anti-HCV antibody response(s) (seroconversion) 
are usually detected by weeks 8-12 post-infection [64, 133]. Early studies showed that 
antibodies targeting the hypervariable region-1 (HVR1) of the E2 glycoprotien of HCV are 
neutralizing in vitro and in vivo [150, 151], and might select for mutations in the envelope 
region [152]. However, a chimpanzee study showed that clearance was not associated with 
the generation of anti-envelope antibody response in 28 animals [153] and persistence 
could not be correlated with viral escape by mutations in the E1-E2 regions (especially 
HVR1 region) [153, 154]. Moreover, another chimpanzee study demonstrated that the 
presence of antibodies targeting HVR1 during acute infection was associated with the 
development of chronic infection suggesting that they do not mediate protection in vivo 
[113]. On the other hand, Law et al. [155]  reported the identification of monoclonal 
neutralizing antibodies that could protect against heterologous viral infection, and the 
results obtained by Lake-Bakaar et al. [156] through using reversible B-lymphocyte 
depletion suggested a protective role of B cells. These inconclusive in vitro and in vivo data 
suggest that the role of antibodies in HCV infection needs further investigation.  
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1.4.2.2. Cell Mediated Immunity (CMI) 
CMI is mediated through CD8+ and CD4+ T cells. CD8+ T cells kill target cells 
displaying viral antigens within the context of their MHC class I molecules [148]. CD4+ T 
cells are known to play an essential role in priming and sustaining cytotoxic CD8
+
 T-cell 
(CTL) responses [157]. CMI is of special importance in immunity against non-cytopathic 
viruses like HCV [6].  
1.4.2.2.1. CD4+ T cells in HCV infection 
HLA class II restricted T-cell responses were shown to be of direct impact on the 
outcome of acute HCV infection [158, 159] and some HLA class II alleles were either 
associated with resolution or chronicicty (e.g. HLA-DRβ1*0101 was associated with 
clearance, whereas HLA-DRβ1*0701 was associated with HCV persistence) [160-162]. 
Also, there is an association between the prevalence of either helper T-cell subtype 1 (Th1) 
or Th2 cytokine profiles and resolving acute HCV infection or developing persistent 
disease, respectively [163], all of which suggests the existence of a correlation between the 
quality of CD4+ T-cell responses and the outcome of acute infection.  
The three major characteristics of a successful helper T-cell response is being early, 
vigorous and multi-specific, and in patients that proceed to chronicity either one or more of 
theses were lacking [46]. Early CD4+ responses were temporally and kinetically correlated 
with control of viraemia and patients who were able to clear the infection spontaneously 
during the acute phase demonstrated CD4
+
 T cells able to proliferate efficiently following 
stimulation by total recombinant protein and had a robust IFN-γ production (Fig. 1.6 c) 
[120, 164].  
Another key factor is the breadth of the CD4+ helper T cell targeting 
immunodominant epitopes. Patients who spontaneously resolved the infection were shown 
to target multiple HCV epitopes (up to 14) mapped to Core and non-structural regions. 
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Several MHC-II restricted epitopes were recognized by CD4+ T cells from resolved 
patients even years after clearing the virus [164]. Some subdominant CD4+ T-cell activities 
may be observed, but this could occur even after the viraemia has already been controlled 
[165]. The hierarchy of CD4+ T-cell responses was preserved even during secondary 
infection years later [165]. 
In conclusion, an early functional CD4+ T-cell response directed against multiple 
immunodominant epitopes predicts control of viraemia, while in cases that develop chronic 
disease CD4+ T cells are either absent or if present are functionally altered or target fewer 
epitopes [158, 166-168]. This indicates that contraction of the CD4+ T-cell population and 
its failure in sustaining a robust CD8+ T-cell effector response is a hallmark of HCV 
persistence [46]. 
1.4.2.2.2. CD8+ T cells in HCV infection 
Several studies in humans and chimpanzees demonstrated that the three success 
factors for CD8+ T-cells are the same as for CD4+ T-cells; the onset, the strength and the 
breadth of the response, are all correlated with the ability to clear the virus during acute 
infection [120].   
Several studies have more precisely defined the role of CD8+ T cells as compared 
to helper T cells. In a chimpanzee study all the animals that were unable to mount a 
functional CTL response developed chronic infection, while in spontaneously resolved 
animals the onset of the cytotoxic T lymphocyte (CTL) response coincided exactly with the 
termination of infection [169]. Using the MHC-I tetramer staining technique which enables 
the detection of cells targeting an individual epitope, strong correlation of outcome could be 
established with functional CD8+ T cells targeting a specific HCV epitope, as their 
detection at high frequencies in the blood and liver of humans and chimpanzees is 
temporally and kinetically associated with the control of the viraemia [46]. As much as 8% 
of the total CD8+ cells in the blood targeting a single immunodominant HCV epitope could 
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be detected in spontaneously resolved patients [120] and several fold higher detected in the 
liver [170]. These tetramer positive cells displayed markers of T-cell activation (e.g. CD38, 
CD69 and MHC II) [114, 171]. Furthermore, multi-specificity is more pronounced in 
humans and chimpanzees able to clear the infection, with eight or nine different epitopes 
recognized simultaneously by CD8+ form the blood and liver [120, 169]. Genetic 
restriction was shown to have an impact on HCV-specific T-cell responses, with some 
HLA-B alleles (e.g. HLA-B*27) demonstrating a strong association with clearance, while 
chronically infected individuals expressing HLA-B*27 demonstrated epitope 
polymorphisms [172].      
1.4.2.2.3. Memory CMI and recurrent infection  
Mehta et al. [173] demonstrated that individuals who were previously exposed to 
HCV and successfully cleared the infection were 12 times less likely than their naïve 
counterparts to develop persistent viraemia. This may be due to the fact that individuals 
able to spontaneously clear HCV acute infection are able to generate a robust memory T-
cell population [174]. A group of women infected from a common source were followed up 
several years after the initial infection. It was found that those who spontaneously resolved 
the infection possessed HCV-specific CD4+ and CD8+ T cells that could be detected in 
their peripheral blood even after 20 years post-clearance [164]. Phenotypic characterization 
of HCV-specific CD4+ and CD8+ T cells in spontaneously resolved cases showed they 
were expressing the lymphoid homing marker CCR7+ and CD45RO, both characteristic of 
memory T cells [175, 176]. Upon rechallenging spontaneously resolved chimpanzees with 
HCV isolates even from a different genotype the duration of infection was significantly 
shorter, and was associated with the detection of IFN-γ producing CD4+ and CD8+ T cells 
at a higher frequency and as early as day 14 into the second infection compared to 8 weeks 
into the primary infection [176-179]. The role of memory T cells was further verified by 
using antibody-mediated depletion of either CD4+ or CD8+ T cells. CD4+ T-cell depletion 
was associated with low level viraemia but memory CD8
+
 T cells were able to partially 
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control the viraemia [157], whereas memory CD8+ T cell depletion led to a significant 
delay of viraemia control, and this control coincided with the re-detection of the cells [121]. 
Taken together these data underscore the importance of memory T cells in conveying 
protective immunity upon repeated infection, and show that it mainly reduces the level of 
viraemia and the duration of infection rather than conferring ‘sterilizing-immunity’ [133].  
1.4.3. Failure of the immune response against HCV 
Several factors contribute to the failure of the HCV-specific immune response to 
contain HCV infection leading to the high rate of HCV persistence. These factors are due to 
either direct failure of the HCV-specific immune response or indirect effects of HCV 
proteins on components of the immune system. Inadequate HCV-specific immune 
responses may be due to the primary failure of one or more of the components of the 
immune system from the start of the infection or their exhaustion over time. Nevertheless, 
even an initially functional HCV immune response could be subverted by viral evasion 
strategies.  
1.4.3.1. Primary failure of the HCV-specific immune response 
Defects in antiviral signalling pathways or in functions of innate immune cells were 
both reported in persistently infected HCV patients. NK numbers and functions, especially 
cytotoxic activity, were shown to be lower in chronic hepatitis C patients compared to 
healthy donors [180-182]. Some reports demonstrated a reduction in number of mDCs and 
pDCs, but these studies reported them to be fully functional on the individual-cell basis 
[183-185]. In contrast, other reports demonstrated impaired antigen presentation in DCs 
from chronic HCV patients due to defects in the ability of natural killer cells (NKs) to 
derive DC maturation as shown in an in vitro culture system [186]. DCs from chronic HCV 
patients were also reported to have impaired allostimulatory functions for HCV-specific 
CD4+ T cells [187-189], but evidence confirming this dysfunctionality against other 
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viruses in the same patients are lacking. On the other hand, multianalyte profiling (MAP) of 
the key chemokines and cytokines involved in pDC activity suggested/indicated that they 
are fully functional in chronic hepatitis C patients [190]. 
Primary defects in adaptive immune cells’ frequency and/or functions were 
consistently reported from chronically infected patients; CD4+ T-cell responses are very 
weak or even absent in individuals with chronic HCV [175]. When present, they were 
either non-functional or transiently controlled the infection then decreased in frequency and 
their function waned just before the viraemia rebounded (Fig. 1.6 a, b) [135]. In some of 
these chronic cases even if HCV-specific CTL responses could still be detected –albeit at 
minimal level– CD4+ helper T-cells were functionally absent [164, 166, 174, 191], as 
indicated by decreased cytokines’ production, especially failure to secrete interleukin-2 (IL-
2) [192]. CD8+ T cells in chronic patients were also reported to be anergic or of an arrested 
developmental phenotype (CD27
+
CD28
+
) with less potent cytotoxic functions than the 
more differentiated ones [193, 194], which were also impaired in cytotoxic function and 
proliferative capacity [171, 194], described as a ‘stunned’ phenotype [114, 120]. 
Furthermore, CD8+ T HCV-specific cells from chronic individuals were shown to be 
exhausted, as demonstrated by the high expression of programmed cell death 1 (PD-1) 
receptor [195], and their functions restored by its blockade [196]. Other studies argued that 
PD-1 levels of expression did not correlate with the outcome of acute HCV infection [197, 
198]. Recently, it was proposed that PD-1 and cytotoxic T lymphocyte associated antigen-4 
(CTLA-4) contribute synergistically to CTL exhaustion [199]. Nevertheless, the defects in 
HCV-specific CTLs in patients with persistent infection are not due to generalized 
immunosuppression, as the CTL responses against other viruses (as influenza, Epstein-Barr 
and cytomegalo viruses) are normal [17, 200].  
Suppression of HCV-specific immunity can contribute to chronicity. CD4+ T-cells 
producing the anti-inflammatory cytokines IL-4 and IL-10 were detected in chronic patients  
[163, 201] and the percentage of CD4+ CD25+ regulatory T cells (Tregs) expressing  the 
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forkhead transcription factor 3 (FoxP3+) was shown to be elevated in chronic versus 
spontaneously resolved or infection naïve individuals [202]. A study also showed an 
unexpectedly high proportion of CD4+ cells in liver biopsies from chronic patients, and 
their role in HCV persistence was supported by the increase in populations of functional 
CD8+ T cells upon their depletion [203, 204]. Moreover, Tregs derived from chronically 
infected patients were significantly more suppressive than those from spontaneously 
resolved ones [205]. 
Finally, the liver as an immunological milieu is associated with the induction of 
tolerance despite its ability to sustain effective responses [206]. This suggested that primary 
contact of T cells with sinusoidal endothelial cells in the liver rather than lymph nodes 
typically results in tolerance [207, 208], and this ‘abortive’ activation could be the reason 
why HCV-specific T cells with the highest avidity undergo functional ‘silencing’ [209].  
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Figure 1.6: Successful versus unsuccessful CMI response during acute HCV infection.   
Viraemia falls from the high initial level to a lower stable level irrespective of the outcome. 
a, In case of weak CD4+ and CD8+ T cell responses from the beginning, no control of 
viraemia is observed. b, Initial CD4+ and CD8+ T cell responses could be able to 
transiently control the viraemia, but as the CD4+ T cell response contracts and functions 
wane the viraemia rebounds. c, Early, strong and sustained CD4+ and CD8+ T cell 
responses are able to control and clear the viraemia.       
(Adapted from Bowen DG and Walker CM, Nature Insight Review, 2005) [117] 
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1.4.3.2. Viral evasion strategies  
Several HCV proteins inhibit specific steps in the intracellular antiviral signalling 
pathways e.g. E2 and NS5A bind protein kinase R (PKR) [210], NS5A inhibits 2’,5’-
oligoadenylate synthetase (OAS) which triggers RNAse L [211] and the NS3/4A encoded 
serine protease blocks RIG-I signalling [212]. 
HCV-E2 recombinant glycoprotein engagement to CD81 receptor was reported to 
directly inhibit NK cytotoxicity and IFN-γ production in HCV chronic patients [213, 214]. 
However, a recent report showed that envelope glycoproteins when expressed as a part of 
HCV virus particles do not modulate NK function [215]. The hindrance of DC functions by 
uptake of HCV proteins has been reported, but is still controversial [216-218]. Impaired 
antigen presentation in DCs from chronic HCV patients due to defects in the antiviral 
signalling pathways within DCs was reported, and Rodrigue-Gervais et al. [219] correlated 
this to the viral load within DCs. Whether these defects were restricted to liver-DCs 
remains to be carefully studied [133]. The NS3/4A encoded serine protease alters the 
function of the secretary apparatus in infected cells inhibiting transfer of glycoproteins, 
which suggests interference with MHC-I presentation of viral peptides [220]. 
Mutational escape within targeted epitopes is the most commonly observed evasion 
strategy in RNA viruses. HCV possesses an error-prone RNA dependant RNA polymerase 
(RdRp) causing mutation at a high rate of ~2x10
–3
 base substitution per HCV-genome site 
per year [49]. In cases that develop chronic disease, mutations were observed in the E2 
region that lie within or outside the CD81-binding site, thus preventing recognition by 
nAbs [221, 222]. No escape mutations were noticed in MHC II restricted epitopes. This 
may be due to the lower selection pressure exerted by CD4+ T cells [223]. In contrast, lack 
of sufficient CD4+ T-cell help combined with the fact that functional CTL response is 
inherently delayed for up to 8 weeks after the commencement of infection [121, 224] 
causes CTLs to exert sub-optimal immune pressure on their corresponding viral epitopes 
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not enough to clear the virus, yet selects for the resistant variants with the highest 
replication-fitness. These resistant variants revert if transmitted to another individual 
lacking the restricting MHC allele, thus removing the selection pressure [225]. This does 
not merely have a micro-effect on the selection of quasispecies of certain viruses that 
become dominantly fixed in the niche of an individual, but also a macro-effect on the viral 
variant(s) pre-dominating the population as a whole [226]. Large scale, full-length HCV 
sequencing revealed certain patterns of HCV sequence evolution correlated to HLA allele 
of the host, providing indirect evidence of selection pressure by HLA-restricted CD8+ T-
cell responses [227]. In a chimpanzee study and human studies, the rate of non-
synonymous mutations in MHC I-restricted epitopes was significantly higher (13-fold 
more) compared to other regions outside T-cell epitopes, indicating that these mutations 
were in response to a CD8+ T-cell imposed pressure [228, 229]. Antibody-mediated 
depletion of CD4+ T cells in chimpanzees was associated with low level viraemia but 
memory CD8
+
 T cells were able to partially control the viraemia associated with the 
emergence and selection for escape mutants [157]. With escape mutations, even a multi-
specific T-cell response can be overcome [157], and in some cases specific mutations in 
one epitope were associated with the persistence [230] suggesting that mutations in a 
fraction of the targeted epitopes is enough to achieve an optimized immune-
escape/replication-fitness balance needed by the virus to establish a persistent infection 
[229, 231, 232]. 
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1.5. HCV treatment 
Interferon-α (IFN-α) was shown to have a positive effect on patients with NANB 
hepatitis in 1986, before HCV was cloned [233]. The first regimen introduced was IFN-α 
monotherapy for six months with a success rate of 6-12%. Prolonging the treatment 
duration to 12 months increased the rate only slightly to 16-20% [234]. The addition of the 
nucleoside-analogue antiviral ribavirin increased the rate to 35-40% [235]. By covalently 
binding IFN-α to polyethylene glycol (PEG), PEG-IFN molecule was generated with better 
pharmacokinetics and a longer half-life boosting the success rate to 56% [236-238].  
1.5.1. Treatment regimens  
The only approved therapy for HCV at present is pegylated-IFN-α (PEG-IFN) 
based therapy. The recommended regimen for chronic hepatitis C is a combination of PEG-
IFN weekly injection and oral ribavirin twice daily [239, 240] for 48 weeks in patients 
infected with genotypes 1 and 4, and 24 weeks for genotypes 2 and 3, and sometimes with a 
lower ribavirin dose [237]. Current clinical guidelines suggest that patients diagnosed with 
acute hepatitis C be observed for 12 weeks into the infection; if spontaneous clearance does 
not occur treatment should be offered [241]. Treatment during the acute phase is usually for 
24 weeks although some protocols use shorter periods with genotypes other than genotype 
1. It was demonstrated that combining PEG-IFN with ribavirin does not improve the 
response in acute treatment, so it is dispensable [242, 243]. Interestingly, the treatment 
duration and sustained virological response (SVR) rates during the acute phase are not 
correlated with genotype [244]. 
The guidelines recommend stopping the treatment if the patient remained positive 
after 24 weeks of treatment or HCV RNA became detectable between weeks 24-48 [245]. 
Also, “The week 12 early-stopping rule” recommends stopping treatment if the patient does 
not show at least a 2-log decrease in HCV-RNA at week 12, because several studies report 
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94-100% therapy failure in patients who did not [246, 247]. More aggressive induction of 
therapy at higher doses to improve the early virologic response did not improve SVR rates 
[248, 249]. Early stopping of treatment when success is not expected is mainly due to the 
accompanying side effects that range from rash, malaise, hair loss to lymphopenia, marked 
depression and anxiety that might develop into suicidal tendencies [250].  
1.5.2. Patterns of response to therapy 
Responses to IFN-α based therapy falls into three main categories; SVR, relapse 
and non-response (NR). SVR is defined as the lack of HCV detection during treatment that 
continues for six months after the end of treatment. In relapsers there is no detection of 
viraemia during the course of therapy, but the viraemia rebounds after the end of treatment. 
These relapsers could achieve SVR when re-treated but usually with a longer course or a 
higher dose. Non-responders are individuals in whom the viral load does not decrease  
below the level of detection throughout the duration of therapy nor thereafter [251].  
Further classification of treatment responses offers an earlier insight into the 
expected response to therapy, early virological response (EVR) and early virological 
clearance (EVC) define ≥ 2 log decline in HCV-RNA or negative HCV-RNA at week 12 of 
therapy [241]. Also, in 10% of patients who have attained undetectable HCV RNA during 
treatment RNA reappears during therapy, a phenomenon termed ‘breakthrough’ [250]. In 
patients with SVR the reduction in the viral load is biphasic; a short primary phase where 
there is a rapid decline in HCV RNA and it becomes undetectable within 4–24 weeks due 
to direct inhibition of virus replication [250], and a long secondary phase with a slower rate 
of decline attributed to death of infected cells that is either immune-mediated or mediated 
by other mechanisms [252, 253].  
Taking into consideration the high cost and the side effects of IFN-α therapy, 
defining reliable prognostic markers that can predict the response to therapy before its 
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initiation is a critical objective in the HCV field. Some reports demonstrated that elevated 
baseline levels of ISGs in the liver [254], as well as high serum levels of IFN-induced 
mediators (as IP-10) [255, 256] can be predictive of a low response to therapy. Other 
studies argue that the initial decline of HCV RNA is a better predictor of SVR than other 
baseline parameters [257].  
1.5.3. Factors affecting response to therapy 
Several viral and host related factors are correlated with SVR to therapy. The two 
most important viral factors are the genotype and the timing of commencement of therapy 
[251]. Genotype 1a is the most resistant genotype with an SVR rate of 42-46% [236, 238]; 
in contrast genotypes 2 and 3 have an SVR rate of ~80% even with a shorter course of 
therapy [237]. Early initiation of therapy during the acute phase markedly increases the 
SVR rate to 88%, regardless of the genotype [258, 259]. Other viral factors associated with 
a higher SVR rate are lower baseline viral load [251] and greater quasispecies diversity pre-
commencement of treatment [260].  
Ethnicity and absence of accompanying co-morbidities (e.g. human immune-
deficiency virus (HIV) infection, alcohol abuse, renal diseases) are considered the most 
relevant host factors [251], for example African Americans were shown to have a response 
rate of one-half to one-third that of Caucasians [261] and therapy was reported to be less 
effective in HCV/HIV co-infected individuals than in those with HCV alone [262]. Other 
factors correlated with a better SVR rate are female gender, younger age, lower body 
weight and less liver fibrosis [251]. 
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1. 5.4. Mechanisms of action of therapy  
Exogenous IFN-α administration to cell-cultures defective in IFN signalling 
pathways, led to the stimulation of many ISGs, suggesting that its mechanism of action is 
similar to endogenous IFN-α [40, 263-265]. Also, it has modulatory effect on the immune 
response (discussed later). 
Ribavirin is a nucleoside (guanosine) analogue that was already available since the 
seventies. When tested in the early nineties against HCV, it had no effect on decreasing 
viral titres in patients’ sera [266]. Nevertheless, when used in combination with IFN-α it 
markedly increased the percentage of SVR and decreased the rate of relapse [235]. 
Mechanisms of action of ribavirin are not well understood. One proposed mechanism is 
direct inhibition of HCV replication due to erroneous incorporation by RdRp leading to 
early chain termination. Another mechanism is competitive inhibition of inosine-
monophosphate dehydrogenase (IMPDH) causing GTP depletion. However, neither is the 
main mechanism of action [267, 268]. Other proposed mechanisms include acting as a viral 
mutagen driving the virus towards an ‘error catastrophe’ producing viruses with reduced 
infection ability [269], altering the Th1/Th2 balance in favour of Th1 that potentially 
improves response to therapy [270] and suppressing interleukin 10 (IL-10) production 
[271]. 
1.5.5. Novel therapies and vaccine trials 
Novel therapies have various approaches targeting different steps in the HCV 
replication cycle. A novel class of viral entry inhibitors based on cyclic D,L-α-peptides is 
currently under investigation [272]. Being essential for viral protein processing, replication 
and a major determinant of HCV resistance, NS3/4A serine protease is the most attractive 
target for therapy trials. The most promising protease inhibitor was BILN 2061, but 
research was stopped at Phase II of the clinical trial due to potential cardiotoxity [273] and 
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the other protease inhibitor is VX-950 in Phase Ib of trials [274]. Other viral-enzyme 
inhibitor trials adopt the classical approach of inhibiting the NS5B (RdRp) function, being 
either nucleotide analogues [275] or non-nucleotide analogues [276, 277]. Most recently, 
short interfering RNA (siRNA) as well as short hairpin RNA (shRNA) were shown to 
block the replication of HCV in tissue culture [278] providing the basis for clinical trials on 
RNA-based therapeutic candidates for HCV infection [279]. 
Other therapies aim at restoring an effective immune response. Whether they have a 
potential is questionable, taking into consideration the limited responses detected in chronic 
patients [280]. Immunomodulatory agents as TLR agonists, especially TLRs 7 and 9, have 
started to show their potential in controlling HCV infection in patients with different 
genotypes, reducing the viral load by 90% [281]. A therapeutic vaccine based on seven 
HCV peptides is already in phase II clinical trial [282]. 
So far, no preventive vaccine exists for HCV and vaccine development remains a 
great challenge, taking into consideration that the immune correlates of protection are still 
under investigation, as well as the heterogeneity of the viral sequences. Vaccines based on 
peptides from E1-E2 or Core [283] and genetic vaccines encoding for Core-E1-E2, NS3/4A 
or the complete NS region [284-286] are in various phases of clinical trials. Some of these 
vaccines (especially the ones not containing E1-E2) induced only T-cell responses. This 
underscores the importance of studying the role of B-cell responses and neutralizing 
antibodies to vaccine efficacy.  
1.5.6. Role of the immune system in the response to therapy 
In addition to its direct antiviral actions, IFN-α has an important impact on the 
immune status by activating innate immunity through NK stimulation which aids DC 
maturation, as well as enhancing adaptive immunity through promoting survival of T cells 
–by preventing T-cell apoptosis– and enhancing T-cell proliferation [287], suggesting a role 
for the immune response in the success of therapy. 
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The few studies on the correlation between response to therapy and the HCV-
specific immune response, especially T-cell responses, showed discrepancies. For studies 
on patients receiving IFN-α therapy during the acute phase, Kamal et al. [58] showed that 
multispecific HCV-specific CD4+ T-helper type 1 responses were enhanced compared to 
their baseline activity in patients who cleared HCV versus untreated patients or non-
responders. However, Lauer et al. [59] showed that CD8+ T-cell responses decreased as the 
virus was controlled. These findings were similar to the ones reported by Rahman et al. 
[60] showing that HCV-specific T-cell responses gradually decreased in SVRs until they 
disappeared and the only patient with a sustained immune response was the one who 
developed a rebound in viraemia. For patients receiving therapy during the chronic phase, 
Kamal et al. [288] demonstrated that SVR may be due to the ability of PEG-IFN to induce 
and maintain significant multispecific HCV-specific CD4+ T-helper 1 responses. In 
contrast, Barnes et al. [289] found no significant enhancement in the T-cell responses 
whatever the response to therapy was. The latter reported only a transient enhancement in 
proliferative responses which they considered unreliable as a marker of immune activation, 
being often not associated with functions such as IFN-γ production. 
 
 
 
 
 
 
 
  
35 
 
1.6. Hypothesis and objectives  
One of the most understudied areas in the field of HCV is the antiviral and 
immunomodulatory mechanisms of the current standard of care therapy, as well as host and 
viral factors that dictate the differential response to therapy. Understanding the mechanisms 
of action of current treatments would have important implications in the development of 
novel therapies. Multiple studies have clearly demonstrated that a successful immune 
response capable of spontaneously clearing HCV is mediated mainly by the adaptive arm of 
the immune response, particularly early, multispecific and sustained cell-mediated 
immunity (CMI). CD8+ T-cells are indispensable in clearing the virus, but not without the 
sustained support of CD4+ T-cells. Individuals who fail to mount or sustain such a response 
usually progress to a chronic infection with persistent viraemia [46, 120]. In contrast, 
studies focusing on elucidating the role of an effective CMI in the success of IFN-therapy 
are inconclusive and somewhat controversial [58-60, 288, 289].  
Given the indispensable role of the immune system in clearing natural acute-HCV 
infection, and taking into consideration the immunomodulatory effects of therapy, we 
hypothesized that success of IFN therapy is likely related to restoration of a fully functional 
immune response in individuals who achieve a SVR to therapy, especially if initiated early 
during the acute phase of the infection. 
The objective of this project was to understand the influence of the current therapy 
on the host’s immune response and whether the success of therapy in achieving SVR relies 
on the restoration of an effective immune response depending on the timing of the initiation 
of therapy relative to the infection period.  
The very early studies tackling the role of an effective CMI in the success of IFN 
therapy lacked some important determinants due to technical limitations at the time. These 
early studies focused on studying one or two parameters of T-cell function (e.g. IFN-γ 
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production) or relied on the proliferative capacity as evidence of effective immunity against 
HCV, and most used recombinant proteins to screen for functional cells [58, 60, 288]. With 
the technical advances in multiparametric flowcytometry and studies in other viral 
infections, it became obvious that a multiparametric approach examining several functions 
simultaneously i.e. poly-functionality is essential to study immunity against chronic viral 
infections including HCV and understand the role of the host immunity in determining the 
response to therapy [290, 291]. Also, the use of tetramer staining techniques allowed the 
dissection of responses targeting different specific epitopes [292]. Finally, results of earlier 
studies were difficult to interpret because of the different patient populations studied, 
different therapeutic regimens and unclear definition of acute HCV infection [58-60].  
Hence, we planned the current study to perform extensive multiparametric analysis 
of immunity against HCV, immune failure and restoration after therapy in a well defined 
cohort of acute and chronic HCV infected patients. We were able to accurately define acute 
HCV infection by following-up HCV negative individuals from cohorts at high risk of 
infection (e.g. IDUs) at short intervals, enabling us to define the early immune factors that 
influence the outcome of acute HCV, and to identify immune markers that could predict 
spontaneous resolution. The specific aims of the study were to study both host and viral 
factors involved in the differential response to IFN therapy, as well as determine immune 
factors associated with SVR. To achieve this, we performed longitudinal analysis of the 
immune responses and host-virus interaction in acute and chronically infected individuals, 
before, during and after receiving IFN-α based therapy, thus enabling us to define possible 
immune factors that might contribute to enhanced response to IFN therapy, as well as 
identifying immune markers that could predict the differential response to therapy. A cross-
sectional study at the time point right after clearing the virus or at the end of treatment (for 
patients with SVR) was performed to focus on the possible mechanisms involved in viral 
clearance in response to therapy. We used both peptide pools to screen for immune 
responses against HCV in general, as well as MHC class I tetramers to detect HCV-specific 
T cells targeting a specific epitope. We applied a multiparametric approach when defining a 
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successful HCV-specific T-cell response, through assessing individual functions, poly-
functionality analysis, proliferative capacity and phenotype.  
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2.1.1. Abstract 
The majority of acute hepatitis C virus (HCV) infections progress to chronicity and 
progressive liver damage.  Interferon-alpha (IFN-α) antiviral therapy achieves the highest 
rate of success when administered early during the acute phase but the underlying 
mechanisms are unknown.  We used a panel of MHC class I tetramers to monitor the 
phenotypic and functional signatures of HCV-specific T cells during acute HCV with 
different infection outcome and during early interferon therapy. We demonstrate that 
spontaneous resolution correlates with the early development of poly-functional (IFN-γ+, 
IL-2+ and CD107a+) virus-specific CD8+ T cells. These poly-functional T cells are 
distinguished by the expression of CD127 and Bcl-2 and represent a transitional memory T 
cell subset that exhibits the phenotypic and functional signatures of both central and 
effector memory T cells.  In contrast, HCV-specific CD8+ T cells in acute infections 
evolving to chronicity were CD127
lo
, Bcl-2
lo
, exhibited diminished proliferation and 
cytokine production and eventually disappeared from the periphery. Early therapeutic 
intervention with pegylated IFN-α (PEG-IFNα) rescued CD127
hi
, Bcl-2
hi
 poly-functional 
memory T cells.  These cells were detectable for up to 1 year following discontinuation of 
therapy.  Our results suggest that poly-functionality of HCV-specific T cells can be 
predictive of the outcome of acute HCV and that early therapeutic intervention can 
reconstitute the pool of long-lived poly-functional memory T cells.  
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2.1.2. Introduction 
Hepatitis C virus (HCV) infection resolves spontaneously during the acute phase in 
a minority of infected individuals while the majority develops persistent viraemia and 
chronic hepatitis over a period of years or decades (28).  Understanding the immune 
response leading to spontaneous resolution during acute HCV has been hampered by the 
asymptomatic nature of the disease.  Studies in the chimpanzee model and high risk 
populations like intravenous drug users (IDUs) or healthcare workers following HCV 
exposure have demonstrated the absolute requirement for the CD8+ and CD4+ HCV-
specific T cell responses to prevent viral persistence (reviewed in (12, 50)).  A cellular 
immune response is induced in most infected individuals resulting in spontaneous 
resolution or transient control of viraemia.  However, this response is not sustained in 
individuals who develop viral persistence.  The inefficiency of this initial immune response 
and viral recurrence in individuals who progress to chronic infection is likely due to the 
loss of CD4+ T cell help (16, 20, 56, 57) and the rapid emergence of viral escape mutants 
in targeted CD8+ CTL epitopes (9).  Individuals who spontaneously resolve HCV infection 
develop long-lived memory T cell responses (54) that can be protective upon re-exposure 
(51).  In contrast, cellular immune responses are mostly undetectable in the blood of 
persistently infected individuals and mostly localized in the liver (19, 27).  Visualization of 
HCV-specific T cells ex-vivo using MHC class I tetramers have demonstrated that HCV-
specific CD8+ T cells are severely impaired in function in chronically infected individuals 
as demonstrated by the lack of proliferation  (60) and cytokine production (22) in response 
to specific antigen stimulation. At present it is difficult to establish if such aberrant 
responses are the cause or the effect of persistent viraemia and T cell exhaustion.  
Memory T cells in humans are classified based on the expression of the chemokine 
receptor CCR7 and CD45RA into 3 subsets: central memory (TCM) defined as 
CCR7+CD45RA- with a high proliferative capacity and lower IFN-γ production, effector 
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memory (TEM) defined as CCR7-CD45RA- with lower proliferative capacity and higher 
IFN-γ production and terminally differentiated effectors (TEMRA) defined as CCR7-
CD45RA+ having the lowest proliferative capacity and highest IFN-γ production (46, 47).  
Additional markers have been used to identify different subsets or maturation status of 
memory T cells like the co-stimulatory molecules CD27 and CD28, IL-7 receptor-alpha 
(CD127) as a marker of cells destined to become memory T cells (29) and programmed 
death receptor-1 (PD-1) as a marker for T cell exhaustion in several viral infections (14).  
Recent studies have associated spontaneous resolution of acute HCV with up-regulation of 
(CD127) (17, 58) and down-regulation of the PD-1 (18, 39, 42, 59).  In contrast, other 
studies have demonstrated that CD127
+
 HCV-specific CD8+ T cells are detectable in 
persistently infected individuals (4, 42) and that PD-1 does not correlate with outcome of 
acute HCV (8, 35), suggesting that PD-1 may not be a marker for T cell exhaustion but 
rather activation.  In addition, virus-specific memory T cells in chronic HCV were shown to 
be arrested at an early maturation stage CD27+CD28+ (3). However, contribution of the 
different memory T cell markers to defining functionally competent HCV-specific T cell 
populations associated with viral clearance and the development of such subsets during 
clearly defined acute HCV infection remain elusive. 
There is no vaccine for HCV and the current therapy, a combination of pegylated 
interferon-alpha (PEG-IFN-α) and ribavirin, is only effective in approximately 50% of 
chronically infected individuals (13). Nevertheless, response to therapy is enhanced if 
started early during the acute phase (32, 34, 62) suggesting progressive damage to the host 
defence system with prolonged infection. The role of the immune response in determining 
the outcome of HCV therapy has been controversial with some studies demonstrating an 
enhanced immune response in individuals who respond to therapy (31, 33) while others 
showing no correlation and even a decline in the immune response following therapeutic 
elimination of the virus (37, 43). Most importantly, comprehensive analysis of the 
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functional and phenotypic signatures of HCV-specific T cells when therapy is introduced 
early during the acute phase is unknown. 
In this study, we used a panel of five MHC class I tetramers and 9 color multi-
parametric flow cytometry to monitor longitudinally the phenotypic and functional changes 
in HCV-specific T cells in a unique cohort of IDUs at high risk of HCV infection, before 
and during acute HCV infections that progressed to spontaneous resolution or viral 
persistence. In addition, we followed a subset of these individuals during early IFN therapy.  
We demonstrate that acute resolving HCV infections are characterized by the early 
development of poly-functional CD127+, Bcl-2+ HCV-specific T cells consistent with a 
transitional effector memory T cell profile.  Most importantly, early therapeutic 
intervention with PEG-IFN-α rescued CD127
hi
, Bcl-2
hi
 long-lived poly-functional memory 
T cells.   
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2.1.3. Materials and Methods 
2.1.3.1. Study subjects and clinical follow-up 
HCV acutely infected subjects were recruited among high risk IDUs participating in 
the St-Luc cohort study or methadone treatment program or presenting to the hepatology 
clinic at St-Luc hospital of the CHUM. This study was approved by the institutional ethics 
committee (SL05.014 and SL05.025) and conducted according to the Declaration of 
Helsinki.  All participants signed informed consent upon enrolment.  Acute HCV infection 
was defined as either i) detection of positive HCV-RNA in the absence of HCV antibodies 
at recruitment followed by seroconversion: patients R1, C2, T1, T4; ii) a positive HCV 
antibody test following a previous negative test in the presence of positive HCV RNA, time 
intervals ranging between 63 and 126 days: patients R2 (126 days), T2 (63 days), T3 (90 
days); and iii) patient C1 presented to the hepatology clinic with symptomatic acute HCV 
including elevated serum ALT levels and HCV-RNA and antibody positive test following a 
high risk exposure.  All patients tested negative for HIV and HBV.  Duration of infection 
was defined as the time (in weeks) from the first positive HCV-RNA test.  Spontaneous 
viral resolution or persistent infection was defined as the absence or presence of HCV RNA 
at 12 weeks post enrolment.  In accordance with the clinical guidelines at the time, 
interferon therapy was offered to participants if they tested HCV RNA positive at 12 weeks 
after HCV detection (61).  Patients who accepted treatment received 12-16 weeks of PEG-
IFNα−2a (Pegasys) (Roche diagnostics, Welwyn Garden City, Hertfordshire, UK) (180 
µg/week) and no ribavirin.  HLA typing was performed by the Core facility of the FRSQ 
AIDS and Infectious Disease Network (SIDA-MI), Montreal, QC, Canada using standard 
SSP-PCR high resolution techniques as previously described (63). 
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2.1.3.2. HCV RNA testing and quantification 
Qualitative HCV-RNA tests were performed using automated COBAS 
AmpliPrep/COBAS Amplicor HCV test, version 2.0 (sensitivity 50 IU/ml) (Roche 
Molecular Systems, Inc., Branchburg, NJ). HCV genotyping was done using standard 
sequencing for the NS5B region and HCV RNA was quantified by the COBAS Amplicor 
HCV Monitor test, Version 2.0 (sensitivity 600 IU/ml) (Roche Molecular Systems).  Both 
tests were performed by the Laboratoire de santé publique du Québec (LSPQ) (Ste-Anne-
de-Bellevue, QC) as part of the clinical follow-up of patients. Additional HCV RNA 
quantification was performed using an in-house quantitative real time PCR assay adapted 
from Takeuchi T et al. (55).  Briefly, total viral RNA was extracted from 200 µl of plasma 
collected in EDTA using QIAmp Mini Elute Spin Kit (Qiagen, Valencia, CA) according to 
the manufacturer’s protocol and eluted in 25 µl.  Quantitative PCR was performed in 
duplicate using 10 ul of extracted RNA in a 25 µl reaction volume of one step RT-PCR 
using QuantiTect Probe RT-PCR kit (Qiagen). The following primers were used: Forward 
primer: 5’-CGGGAGAGCCATAGTGG-3’, Reverse primer: 5’-
AGTACCACAAGGCCTTT-3’, Probe: 5’-6-FAM-CTGCGGAACCGGTGAGTACAC-
IBFQ-3’.  Real time PCR was performed using Rotor Gene 3000 Instrument (Corbet 
Research, Sydney, Australia) as follows: reverse transcription for 30 min at 50ºC, PCR 
initial activation step 15 min at 95ºC followed by 50 cycles of 2-step PCR(15 sec at 95ºC 
and 60 sec at 58 ºC).  Plasma RNA concentration was calculated using Rotor Gene 6 
analysis software (Corbet Research) from a standard curve prepared using standard patient 
plasma of known HCV-RNA content. 
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2.1.3.3. Peptides and peptide-HLA class I tetramers. 
Overlapping peptides corresponding to the HCV-H77 genotype 1a polyportien 
reference sequence used in the ELISpot screening assays were obtained from the 
Biodefense and Emerging Infections Research Resources Repository (BEI Resources), 
Manassas, VA.  All other peptides were synthesized by Eastern Quebec Proteomics Core 
Facility, Quebec, QC, Canada. MHC class I tetramers were synthesized by the National 
Immunomonitoring Laboratories (NIML), Montreal, QC, Canada and are as follows: HLA-
A1 restricted HCV NS3 peptide 1436–1444 (ATDALMTGY), HLA-A2 restricted HCV 
NS3 peptide 1073–1081 (CINGVCWTV), HLA-A2 restricted HCV NS3 peptide 1406–
1415 (KLVALGINAV), HLA-B7 restricted HCV Core peptide 41–49 (GPRLGVRAT) and 
HLA-B8 restricted HCV NS3 peptide 1395–1403 (HSKKKCDEL), and control tetramers 
as: HLA-A2 restricted CMV pp65 peptide 495–503 (NLVPMVATV), HLA-B7- restricted 
CMV pp65 peptide 1014–1023 (TPRVTGGGAM) and HLA-A2 restricted FLU peptide 
1007–1015 (GILGFVFTL).  
2.1.3.4. Flow-cytometry antibodies and reagents 
Directly conjugated antibodies against the following surface molecules were used: 
CCR7-PE-Cy7 (clone 3D12), CD3-APC (clone UCHT1), CD3-Pacific Blue (clone SP34-
2), CD4-Pacific Blue (clone RPA-T4), CD8-Alexa Fluor 700 or –Pacific Blue (clone RPA-
T8), CD28-PerCP.Cy5.5 (clone L293), CD127-Alexa Fluor 647 (clone HIL-7R-M21) and 
PD-1-APC (clone MIH4), all from BD Biosciences, San Jose, CA; CD27-APC-Alexa Fluor 
750 (clone 0323) (eBioscience, San Diego, CA); CD3-ECD (Clone UCHT1) and CD45RA-
ECD (clone 2H4) (Beckman Coulter, Marseille, France); CD127-Alexa Fluor 488 (clone 
HCD127) (Biolegend, San Diego, CA). The following intracellular antibodies were used: 
IL-2-PE (clone MQ1-17H12), IFN-γ-Alexa 700 (clone B27), Bcl-2-FITC (clone 100), 
CD107a- PE-Cy5 (clone H4A3) all from BD Biosciences. 
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Live cells were identified using Aqua Live/Dead fixable dead cell Stain Kit 
(Molecular Probes, Eugene, OR) according to the manufacturer’s protocol.  Fluorescence 
minus one (FMO) control stains were used to determine background levels of staining. 
Multiparameter flow cytometry was performed using a standard BD LSR II instrument 
equipped with blue (488 nm), red (633 nm), and violet (405 nm) lasers (BD Biosciences,) 
to systematically perform 9 colors staining using FACSDiva software (BD Biosciences). 
Compensation was performed with single fluorochromes and BD CompBeads (BD 
Biosciences).  Data files were analyzed using FlowJo software version 8.6.3 for Mac (Tree 
Star, Inc., Ashland, OR).  Polyfunctional data was exported using Boolean Gates in FlowJo 
and further analysed using PESTLE software (version 1.5.4) and SPICE software (version 
4.1.6) obtained from M. Roederer, National Institutes of Health (NIH), Bethesda, MD.  
Polyfunctional T cells were defined as viable CD3+, CD8+ cells that produce IFN-γ, IL-2 
and express CD107a simultaneously. A cutoff of 0.02% of specific IFN-γ production was 
considered for any poly-functionality analysis. 
2.1.3.5. Multiparametric phenotypic characterization of HCV-specific T cells. 
All flowcytometric assays were performed on cryopreserved samples. For 
phenotype analysis, 2.5 x 10
6
 PBMCs were stained with freshly prepared tetramer-PE for 
30-min at room temperature, washed in FACS buffer (PBS 1X, 1% FBS, 0.02% NaN3), 
then stained with surface antibodies for 30 min at 4°C, washed twice in FACS buffer and 
fixed in FACS Fix buffer (PBS 1X, 1% formaldehyde).  For intracellular Bcl-2 detection, 
PBMCs were first stained with tetramers and surface markers, lysed with BD Lysing and 
Permeabilizing Kit (BD Biosciences) according to the manufacturer’s instructions, stained 
with anti Bcl-2 antibody then washed twice and fixed in FACS Fix buffer.  
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2.1.3.6. Intracellular cytokine staining (ICS) and CD107a degranulation assay. 
2 x 10
6 
PBMCs were incubated with anti-CD107a and either DMSO (0.1%) as a 
negative control or HCV peptide (1 µg/ml) at 37°C° in R-10 media (RPMI medium 
(Invitrogen, Carlsbad, CA), 10% FBS).  Following one hour of stimulation, 10 µg/ml of 
Brefeldin A (Sigma-Aldrich) and 6 µg/ml of Monensin sodium salt (Sigma-Aldrich) were 
added and cells were incubated for a total of 16 hrs. Cells were then washed with FACS 
buffer and stained for viability and cell surface antigens, permeabilized using BD 
Cytofix/Cytoperm solution (BD Bioscience) then stained with anti-IL-2 and anti-IFN-γ 
antibodies for 30 min, washed twice in BD Perm/Wash buffer (BD Biosciences) and fixed 
in FACS fix buffer.  For analysis, cells were gated on viable CD3+, CD8+ T cells and 
percent specific expression is calculated as the background adjusted function in presence or 
absence of cognate peptide stimulation.  
2.1.3.7. CFSE proliferation assays 
PBMCs resuspended at 20x10
6
/ml PBS were stained with 0.63 µM of 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR) 
for 8 minutes at room temperature. Reaction was stopped with FBS, cells were washed 
three times in PBS, then re-suspended at 2x10
6
 cells/ml in warm R-10. CFSE–labeled cells 
were stimulated for 6 days with or without HCV peptide (final concentration 1 µg/ml) at 
37°C and 5% CO2. Recombinant human IL-2 (20 IU/ml) (NIH AIDS Research and 
Reference Reagent Program, Germantown, MD) was added on day 3. On day 6, cells were 
stained with HCV tetramer(s) and surface antigens as described above.  
2.1.3.8. Cell sorting experiments 
PBMC were labelled and sorted into CD3
+
,CD127
hi
 and CD3
+
,CD127
neg
 
populations using a FACS Aria Instrument (BD Biosciences, San Jose, CA) employing 
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FACS-Diva software.  Sorted cells were collected, washed and suspended in warm R-10 for 
30 minutes before being prepared for CFSE, ICS and phenotypic assays as described above.  
For ICS and CFSE proliferation assays, autologous irradiated PBMCs were added to each 
tube to act as antigen presenting cells at an E:T ratio of 2:1. 
2.1.3.9. HCV epitope sequencing  
HCV RNA was extracted from 140 µl of thawed EDTA plasma using QIAamp 
Viral RNA Mini Kit (Qiagen) according to the manufacturer’s protocol.  HCV RNA was 
reverse transcribed and PCR amplified by the sets of nested primers listed in Table S1.  5-
30 ul of viral RNA were used for a single step reverse transcription and first round PCR 
with 20-100 ρmoles of outer PCR primers using the SuperScript III One-Step RT-PCR 
system with Platinum Taq (Invitrogen).  Briefly, reverse transcription was performed at 
55°C for 45 min, followed by heat inactivation at 94˚C for 2 min.  First round PCR was 
performed directly for 40 cycles (denaturing at 94°C for 30 sec, annealing at 55°C for 1 
min, extension at 68°C for 2 min) and a final elongation cycle at 68°C for 7 min.  First 
round PCR products were purified using PCR Purification Kit (Qiagen) then 5 µl of the 
product was used in the second PCR using the nested set of primers listed in Table S1.  
Nested PCR was performed for 30 cycles (denaturing at 94°C for 30 sec, annealing at 55°C, 
extension at 72°C for 1 min) followed by a final elongation step at 72°C for 15 min.  PCR 
products were purified and cloned in pCR4-Topo (Invitrogen) using the Topo TA cloning 
kit for sequencing (Invitrogen) and sequenced. 
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2.1.4. Results 
2.1.4.1. Identification of acute HCV and longitudinal phenotypic analysis of HCV-
specific CD8+ T cells. 
Eight subjects acutely infected with HCV were identified among IDUs, the group at 
highest risk of new HCV infections, as described in Materials and Methods.  Patients’ 
demographics and characteristics are listed in Table 1.  HLA typing and tetramers used are 
listed in Table 2.  The overall breadth of the immune response was monitored at the earliest 
time point by an IFN-γ ELISpot assay using a panel of overlapping peptides corresponding 
to the HCV-H77 genotype 1a polyprotien reference sequence. As documented in the 
literature, the immune response was broader in the patients who resolved spontaneously 
(data not shown).  A panel of 5 different HLA-class I tetramers corresponding to predefined 
dominant HCV responses were then used together with a comprehensive 9 color panel of 
phenotypic markers for T cell maturation (CD27, CD28), T cell memory (CCR7, CD45RA, 
CD127) and T cell exhaustion (PD-1). Control tetramers containing Cytomegalovirus 
(CMV) or Flu peptides were used in most patients (Table 2). Representative phenotyping 
results, using A2/NS3-1073 tetramer, from patient R1 with acute resolving HCV and 
patient T4 with chronic evolution are presented in Figures 1A and 1B, respectively.  HCV-
tetramer positive cells were not detectable in patient R1, 9 weeks prior to his first positive 
RNA test or in patient T4 at 2 weeks post detection of viraemia (PDV).  Although NS3-
1073 tetramer frequency was very high in patient R1 as compared to T4 (4.5% versus 0.16 
%), there was no difference in the phenotype of HCV-specific cells in both patients at the 
early stages of infection as cells were primarily: CD27+, CD28+, CCR7-, CD45RA-, 
CD127
lo
, PD-1
lo
.  Nevertheless, as patient R1 eliminated the virus and despite a decline in 
the frequency of tetramer positive cells they gradually up-regulated CD127 expression.  
Cells detectable at a late follow-up time point at 86 weeks PDV were 93% positive for 
CD127 (Figure 1A).  In patient T4, as viraemia persisted, the tetramer positive cells lost 
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CD127 and up-regulated PD-1 expression (Figure 1B).  Similar results were obtained with 
other patients studied, HCV-tetramer positive detected in all patients early were primarily: 
CD27+, CD28+, CCR7-, CD45RA-, CD127
lo
, PD-1
lo
 (data not shown) and did not change 
as infection progressed to chronicity or spontaneous resolution with the exception of 
CD127 and PD-1.  Re-examining the phenotype of HCV-tetramer+ CD8+ T cells at the 
latest follow-up time point prior to commencement of therapy, demonstrated that CD127 
was up-regulated on HCV-specific CD8+ T cells in patients R1 and R2 who spontaneously 
resolved acute HCV infection (Figure 1C) and slightly upregulated or unchanged in patients 
T1 and T2 who exhibited low viral loads 1,170 and 9,300 IU/ml plasma, respectively 
(Table 1).  Similar to previous reports, PD-1 expression did not necessarily correlate with 
infection outcome (8, 35). Expression was generally low during the early phase of infection 
in all patients but then was up-regulated on HCV positive cells in patients T3 and T4 
(Figure 1C), who also exhibited the highest viral loads around 10
7
 IU/ml (Table 1). 
2.1.4.2. Spontaneously resolved HCV infection is associated with the early 
development of poly-functional T cells. 
Given that we could not establish an early phenotypic marker for T cells associated 
with spontaneously resolved HCV infection except CD127, we hypothesized that CD127 
expression delineates a unique subset of long-lived memory T cells that have antiviral 
effector functions, similar to earlier observations in murine and human viral infections (29, 
30).  To evaluate longevity of the CD127+ cells, we monitored the longitudinal co-
expression of the anti-apoptotic molecule Bcl-2 and CD127 in tetramer positive cells in 
patients R1 and R2.  As illustrated in Figure 2A, A2/NS3-1073 tetramer positive cells in 
patient R1 and B8/NS3-1395 tetramer positive cells in patient R2 expressed low levels of 
CD127 and Bcl-2 at the first detection of viraemia although it was partially controlled (< 
600 IU/ml).  As virus was completely eliminated, tetramer+ cells gradually upregulated 
CD127 and Bcl-2 with distinct enrichment in the CD127+, Bcl-2+ tetramer population that 
represented 81% and 69% of tetramer positive cells at the latest follow-up time point in 
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patients R1 and R2, respectively (Figure 2A).  Furthermore, up-regulation of CD127 and 
Bcl-2 was associated with increased proliferative capacity as observed in a CFSE dilution 
assay (Figure 2B).  The proliferation of A2/NS3-1073 tetramer positive cells increased 
from 44% at the first detection of viraemia to nearly 97% by week 86 PDV despite a 4-fold 
decline in tetramer frequency from 4.5% to 0.95% (Figure 2A) and consistent with a 
memory T cell profile (24-26).  Similarly, proliferation of B8/NS3-1395 specific T cells in 
patient R2 increased gradually from 15% to 95% at the latest follow-up.  Finally, we 
evaluated effector functions including the production of the TH1 cytokine IFN-γ and the T 
cell growth factor IL-2 and cytotoxicity through a CD107a degranultion assay (5) following 
stimulation with the cognate peptide NS3-1073 or NS3-1395.  Representative intracellular 
cytokine staining (ICS) data are demonstrated in supplementary Figure S1.  As illustrated 
in Figure 2C, NS3-1073-specific cells in patient R1 and NS3-1395-specific cells in patient 
R2 produced significant levels of IFN-γ and IL-2 and degranulated as measured by CD107a 
in response to stimulation with the specific peptide.  The major function observed was 
production of IFN-γ either alone or together with IL-2 or CD107a (Supplementary Figure 
S1) .  Most importantly, the mean fluorescence intensity (MFI) of IFN-γ was high, 
suggesting high levels of IFN-γ production on a per cell basis (Figure 2C). 
Given that poly-functionality has been associated with control of several viral 
infections, high IFN-γ MFI and with a central memory T cell phenotype (24-26), we 
defined the poly-functionality of IFN-γ producing cells to estimate the proportion of cells 
producing both IFNγ and IL-2; IFNγ and CD107a; or IFNγ, IL-2 and CD107a 
simultaneously.  Poly-functional T cells (IFNγ+, IL-2+ and CD107a+) were detected at the 
earliest time point studied despite active viral replication.  The proportion of poly-
functional T cells (depicted in red) increased overtime, in particular in the long-term 
memory phase representing 15% and 26% of all IFN-γ producing cells in patients R1 and 
R2, respectively. Most importantly, the majority of HCV-specific cells exhibited at least 2 
functions (Figure 2D).   
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2.1.4.3. Acute HCV with chronic evolution is associated with diminished function and 
rapid loss of HCV-specific T cells 
We hypothesized that HCV acutely infected individuals who develop persistent 
infection fail to develop or sustain poly-functional virus-specific T cells.  We thus 
monitored the phenotype and function of HCV-specific T cells longitudinally in patient C1, 
using two different HCV tetramers A2/NS3-1073 and A2/NS3-1406 (Figure 3A).  
Although the two populations of tetramer positive cells were detectable at a considerable 
frequency of (0.1-0.4%) up to 18 weeks PDV in patient C1, the tetramer positive cells 
remained CD127
lo
, Bcl-2
lo
 (Figure 3A, middle panel).  Furthermore, CD8+ T cells 
interacting with both tetramers became undetectable in the peripheral blood by week 41 
PDV (Figure 3A).  Longitudinal analysis of the functionality of the cells demonstrated 
weak proliferative capacity against the NS3-1073 peptide during the early time points of 
the infection and diminished proliferation overtime (Figure 3A, middle panel).  
Furthermore, ICS analysis in response to stimulation with a mixture of the NS3-1073 and 
NS3-1406 peptides demonstrated very low or undetectable cytokine production or CD107a 
degranulation.  Poly-functionality could not be assessed due to the very low level of IFN-γ 
production.  Similar results were observed in patient C2 using B7/Core-41 tetramer with 
disappearance of tetramer positive cells by week 17 PDV, low level expression of CD127 
and Bcl-2 on tetramer positive cells, diminished proliferation and cytokine production 
(Figure 3B). 
2.1.4.4. CD127 distinguishes a unique poly-functional, memory T cell population 
Given the observed correlation between upregulation of CD127 and increased 
proliferation and effector functions, in particular in spontaneously resolved HCV, we 
sought to confirm that CD127 distinguishes a unique T cell subset destined to become poly-
functional long-lived memory T cells.  We sorted CD3+, CD127
hi
 or CD3+ CD127
neg
 T 
cells form the PBMCs of patient R2 at week 17 PDV.  Post-sort phenotypic 
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characterization using B8/NS3-1395 tetramer demonstrated that indeed CD127+ tetramer+ 
cells were all Bcl-2+ consistent with long-lived memory T cells profile (Figure 4A).  
Furthermore, CD127
hi
 tetramer+ cells proliferated extensively in response to peptide 
stimulation demonstrating proliferation of 99% of tetramer+ cells (Figure 4B) versus 65% 
of tetramer positive cells in the pre-sort sample (Figure 2B).  Proliferation was not 
performed on CD127
neg
 cells due to the limited number of recovered cells.  Finally, ICS 
and poly-functionality analysis demonstrated that the CD127
hi
 population was poly-
functional in response to stimulation with the cognate peptide with production of IFNγ, IL-
2 and degranulation while CD127
neg
 cells produced very little cytokines (Figure 4C), 
despite a higher frequency of B8 tetramer positive cells of 1.58% in the CD127
neg
 versus 
0.25% in CD127
hi
 populations (Figure 4A).  Similar results were observed in patient R1 
using sorted cells from week 57 PDV (Supplementary Figure S2).  These results confirm 
that CD127 indeed marks a distinct population of poly-functional HCV-specific T cells in 
these spontaneously resolved individuals.  
2.1.4.5. Early therapeutic intervention rescues poly-functional long-lived memory T 
cells 
Patients T1, T2 and T3 remained persistently infected for up to 15-22 weeks PDV 
and exhibited predominantly a CD127
lo
 phenotype of HCV tetramer specific T cells since 
the early onset of viraemia (Figure 1C).  In accordance with published data and clinical 
guidelines at the time, showing that most acute resolving HCV cases resolve within the first 
12 weeks of infection and recommending IFN therapy for patients who remain HCV RNA+ 
after 12 weeks (61), the patients received IFN monotherapy with no ribavirin for 12-16 
weeks.  The duration of treatment was based on the reports of Kamal et al. demonstrating 
that treatment administered for 8 to 12 weeks was effective to achieve SVR in genotypes 
other than genotype 1, and among patients who present a rapid virologic response i.e. 
HCV-RNA negative at week 4, regardless of the genotype (32, 34).  
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We hypothesized that early interferon therapy will induce up-regulation of Bcl-2 
and may rescue HCV-specific T cells from deletion as observed in patients C1 and C2 who 
declined therapy.  We thus monitored the phenotype and function of the HCV tetramer-
specific cells in these subjects prior to, during and up to 1 year following discontinuation of 
antiviral therapy.  Patient T1 who exhibited a low plasma viral load at the start of therapy 
(1,170 IU/ml) responded to two HCV tetramers A1/NS3-1436 and A2/NS3-1073.  This 
patient received IFN therapy between 15 and 27 weeks PDV (12 weeks total).  Prior to 
commencement of therapy, A1/NS3-1436 tetramer positive cells were primarily CD127
lo
, 
Bcl-2
lo
 (Figure 5A).  Within 2 weeks of starting therapy, a rapid shift was observed in the 
phenotype of NS3-1436 tetramer positive T cells with up-regulation of CD127 and Bcl-2 
upon virus elimination (Figure 5A).  This patient achieved sustained viral response (SVR) 
defined as absence of HCV-RNA up to 24 weeks post discontinuation of therapy.  A 
CD127+, Bcl-2+ tetramer population was selected for during therapy and remained 
detectable up to 58 weeks post discontinuation of therapy (84 wks PDV) (Figure 5A).  
Similar results were observed in this patient using the A2/NS3-1073 tetramer (data not 
shown), in patient T2 using B7/Core-41 tetramer  (Figure 5B) and in patient T3 who 
exhibited very high viral load (11 x 10
6
 IU/ml) prior to therapy, but nevertheless responded 
to treatment and achieved SVR (Figure 5C).  Furthermore, although the patients exhibited 
different levels of PD-1 expression on HCV-specific T cells, PD-1 expression was down-
regulated in all patients upon viral clearance (data not shown).  The overall expression of 
CD127, Bcl-2 and PD-1 was not affected in total CD8+ T cells in any of the patients 
studied during interferon therapy (data not shown).  Furthermore, control staining using 
CMV or Flu tetramers demonstrated that there was no change in phenotype of these T cell 
populations before, during and after IFN therapy (Supplementary Figure S3) thus 
confirming that the observed phenotypic changes are unique to HCV-specific T cells and 
are related to viral clearance rather than immune modulation by IFN-α. 
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In addition, we monitored the function of HCV-specific T cells using CFSE 
proliferation assays and ICS.  All patients demonstrated a good proliferative response at the 
early stages of infection which increased following initiation of therapy (Figure 5, bottom 
panels), suggesting that proliferation might not be predictive of the outcome of acute HCV.  
In contrast, very weak or no IFN-γ, IL-2 or CD107a expression was detected against the 
various epitopes tested prior to therapy and cells were primarily mono-functional (IFN-γ 
producers) (Figure 6).  A remarked increase in IFN-g MFI, restoration in all functions and 
generation of poly-functional T cells was observed in all patients following the initiation of 
therapy and coincident with virus elimination (Figures 6).  Notably, although HCV-specific 
T cells declined in frequency over time they remained detectable and poly-functional up to 
one year following discontinuation of therapy in all patients studied (Figures 5, 6).  Poly-
functional cells constituted 11-20% of specific T cells at the latest follow-up, suggesting a 
long-lived memory T cell response.  
2.1.4.6. Transient restoration of HCV-specific immune responses during therapy 
followed by loss upon viral recurrence. 
We monitored longitudinally the phenotype and function of patient T4 who 
experienced recurrence in viraemia following the discontinuation of IFN therapy. This 
patient responded to the A2/NS3-1073 tetramer and exhibited very high viral load (Table 1) 
(Figure 7A).  During the first 17 weeks PDV, the NS3-1073 specific cells were mostly 
CD127
lo
, Bcl-2
lo
 (Figure 7A).  This patient underwent IFN therapy for 16 weeks between 
weeks 21 to 36 PDV with recurrence of viraemia at 8 weeks post discontinuation of therapy 
(week 44 PDV).  Given the nature of the cohort studied, it is difficult to discriminate 
whether this recurrence in viraemia is a true relapse or a new infection.  We sequenced a 
stretch of 50 amino acids spanning the NS3-1073 epitope in patient T4 prior to therapy and 
upon recurrence of viraemia on week 44 PDV and observed the same viral RNA sequence 
in (13/13) and (14/14) molecular clones, respectively (data not shown), suggesting that this 
is a recurrence of viraemia and not a new infection. 
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Interestingly patient T4 rapidly developed CD127+, Bcl-2+ HCV-tetramer positive 
cells and demonstrated enhanced proliferative capacity at week 28 PDV (7 weeks post 
beginning of therapy) (Figure 7A).  The cells also became poly-functional as they acquired 
the capacity to produce IFN-γ, IL-2 and CD107a (Figure 7C).  However, the proportion of 
poly-functional T cell declined by week 36 PDV.  NS3-1073 specific T cells remained 
detectable by tetramer 3 weeks later at week 39 PDV, exhibited 65% proliferation (Figure 
7A) but were primarily IFN-γ mono-functional at 88% (Figure 7C) and with lower IFN-γ 
MFI.  Furthermore, as this patient relapsed at week 44 PDV, tetramer positive cells and 
cytokine production were undetectable in peripheral blood (Figure 7A and 7B).  Another 
follow-up time point at week 93 PDV yielded similar results (data not shown).  To confirm 
that the NS3-1073 specific cells were not present at a low frequency undetectable by 
tetramers, we attempted to generate a T cell line from the peripheral blood of this patient 
using repeated peptide stimulation at week 93 PDV.  These attempts were unsuccessful 
suggesting that the NS3-1073 specific cells were either completely eliminated from 
peripheral blood, localized to the liver or were extremely defective in their proliferative 
capacity.   
2.1.4.7. Phenotypic and functional changes observed are not due to changes in 
targeted epitopes. 
To confirm that the phenotypic changes observed overtime are not due to the 
emergence of escape mutations in this region, we sequenced the HCV-epitope region 
targeted in the main tetramers used in this study.  At least two time points were sequenced 
for each patient, early upon recruitment and late prior to starting IFN therapy.  The 
following epitopes were sequenced: A2/NS3-1073, A2/NS3-1406 and A1/NS3-1436.  As 
illustrated in Table 3 the dominant viral sequence in all epitopes did not change in any of 
the patients tested.  A mismatch between the autologous virus sequence and the peptide 
sequence used in the tetramer and ICS assay in patients T1 and T3. In patient T1, a Y → F 
change was detected in the A1 restricted NS3-1436 epitope, this change was previously 
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shown not to influence T cell function (36).  Similarly, an I → V mutation was observed in 
the NS3-1073 autolgous virus sequence of patient T3 which is a natural variant of this 
epitope, previously described (36).  It is unlikely that such a mismatch is responsible for the 
changes in phenotype and function of HCV-specific T cells during therapy. 
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2.1.5. Discussion 
We have performed a comprehensive multi-parametric phenotypic and functional 
characterization of the HCV-specific immune response during clearly defined acute 
infection in a unique cohort of IDUs with spontaneous resolution, chronic evolution and 
during early IFN therapy. We demonstrate that spontaneous resolution is associated with 
early emergence of poly-functional CD8+ T cells.  These poly-functional T cells were 
defined by the expression of CD127 and Bcl-2.  Despite a measurable immune response 
detected at the early time points, HCV-specific T cells failed to upregulate CD127 and Bcl-
2 expression in individuals who developed persistent viraemia and eventually disappeared 
from peripheral blood.  Notably, early therapeutic intervention reconstituted a long-lived 
poly-functional memory T cell response.  
In agreement with previous reports we demonstrate that PD-1 expression does not 
correlate with the outcome of acute HCV (8, 35), except at the highest viral loads.  We also 
demonstrate that spontaneous resolution correlates with up-regulation of CD127 on HCV-
specific cells and intracellular content of the anti-apoptotic molecule Bcl-2, a common 
characteristic of long-lived memory T cells (30).  We further demonstrate that CD127 
expression distinguishes a unique subset of HCV-specific memory T cells bearing the 
phenotypic signature of TEM cells (CCR7-CD45RA-) and yet bearing the functional 
signatures of both TCM (rapid proliferation, high IL-2 production) and TEM (high IFN-γ 
production and cytotoxic potential).  These cells are poly-functional in nature, defined as 
the capacity to produce more than one cytokine, in addition to cytotoxic and proliferative 
capacity (26, 48).  Such poly-functional T cells were recently correlated with control of 
HIV infection (1, 6), response to HIV vaccines (24, 41) and anti-retroviral therapy (44).  
We establish that these poly-functional memory T cells in the context of HCV are: CD27+, 
CD28+, CCR7-, CD45RA-, CD127+, Bcl-2+.  A similar memory T cell subset at a 
transitional or early maturation stage (CD27+, CD28+, CD127+) with a short replicative 
  
61 
 
history and strong telomerase activity was recently described (45).  We propose that this 
poly-functional T cell subset represents transitional effector memory T cells (TTEM) that are 
long-lived but also constitute the first responders upon antigen encounter in the periphery.  
Although this T cell subset is distinguished primarily by CD127 expression, and such 
phenotype was reported in other viral infections like hepatitis B virus (7), it is unlikely that 
CD127 alone can be used as a marker of such polyfunctional memory T cells or to predict 
the outcome of HCV infection or therapy.  Such simplistic models of defining maturation 
of virus-specific T cells and their functional capacity are no longer sufficient but a 
comprehensive systematic phenotypic, functional and even genomic profiling will be 
essential.  Studies using a larger cohort of patients are needed to accurately define the 
phenotypic and functional signatures of these poly-functional T cells and should be 
included in monitoring the efficacy of any protective or therapeutic vaccines for HCV as 
recently suggested for HIV vaccine trials (48). 
Several factors may contribute to the induction of poly-functional T cells and 
establishment of T cell memory (30).  The most important factor is unarguably CD4+ T cell 
help. Indeed, CD4+ T cells play an essential role in establishment and maintenance of 
CD8+ memory T cells in various models of murine and human infections (49, 52, 53).  In 
particular, acute HCV infections that progress to chronicity have been linked to the inability 
to sustain a CD4+ helper T cell response (16, 56, 57).  Depletion studies in the chimpanzee 
model have demonstrated that loss of CD4+ T cells results in loss of function and a decline 
in HCV-specific CD8+ T cells and enhanced emergence of escape mutations in targeted 
CTL epitopes (20).  The role of CD4+ T cell help and the mechanisms of cross talk 
between CD4+ and CD8+ T cells during the memory phase that probably occur via 
interaction with dendritic cells still remain to be elucidated (10, 11).  
Longevity is one of the unique characteristics of memory T cells.  HCV-specific 
memory T cells were detected in spontaneously resolved infections for up to 20 years in 
absence of any detectable viraemia (54).  Similarly, in the present study, we demonstrate 
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that although HCV-specific memory T cells declined over time, they remained detectable at 
a reasonable frequency for up to one year following spontaneous resolution or sustained 
viral response to interferon therapy.  All patients were tested at multiple time points by the 
most sensitive PCR assays (sensitivity 50 IU/ml plasma) and were consistently negative, 
suggesting that HCV-specific T-cell memory is antigen independent and that establishment 
of a long-lived memory response is due to successful viral elimination and prevention of 
persistent T cell activation and exhaustion.  Nevertheless, it is still possible that very low 
level residual virus or intermittent viral replication (40) contribute to long-term 
maintenance of virus-specific memory T cell populations.  
PEG-IFN-α therapy for HCV is most effective when initiated early during the acute 
phase (32, 34, 62) but the potential contribution of adaptive cellular immunity in this 
enhanced response is controversial with several reports demonstrating a decline in the 
immune response during therapy (31, 33, 37, 43).  In the present study, we do not observe 
any significant drop in the frequency of HCV-specific T cells during therapy.  Although, 
we do observe a gradual decline over time, HCV-specific T cells remained detectable for 
up to 1.5 years of follow-up.  Such differences between the various studies might be due to 
the therapeutic regimen or the nature of the dominant immune response generated in each 
patient and how accurately it matches the autolgous virus sequence. 
We demonstrate a major change in the immune response following therapy while 
the circulating viral population remains unchanged, thereby excluding a potential influence 
for viral escape on the immune response to the epitopes studied.  However, we did not 
perform a detailed analysis of viral escape in these patients and it remains an important 
mechanism for HCV immune evasion.  It is still possible that viral escape did occur in other 
regions and may have contributed to viral persistence.  Furthermore, the increased poly-
functionality of virus-specific T cells may induce a new selection pressure and trigger 
mutational escape.  A more comprehensive analysis of poly-functionality in relation to full 
length viral sequencing is essential to elucidate this point. 
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We demonstrate that early therapeutic intervention can rescue a poly-functional 
immune response with the same phenotypic and functional characteristics as memory T 
cells induced following spontaneous resolution.  However, it remains unclear if such 
reconstituted response is the cause or the effect of enhanced virus clearance during early 
therapy.  We favour the hypothesis that re-constitution of a poly-functional immune 
response is a consequence of virus elimination and prevention of continued T cell 
exhaustion similar to acute resolving HCV and other viral infections (30).  It is likely that 
there is a limited window of time when IFN therapy can rescue such a poly-functional 
response before HCV-specific T cells become severely exhausted and eliminated from the 
circulation.  In agreement with this hypothesis, our results demonstrate that HCV-specific 
cells eventually become undetectable in patients C1 and C2, who declined HCV therapy.  
Similarly, several reports in the literature have demonstrated that HCV-specific T cells are 
mostly undetectable in the peripheral blood of chronically infected individuals and mostly 
localized in the liver or targeting epitopes that underwent escape mutations, thus preventing 
exhaustion of the specific T cells.   
It is tempting to speculate that the development of a poly-functional T cell response, 
when treatment is initiated early, will prevent relapse upon discontinuation of therapy. The 
inability to rescue such a poly-functional response when treatment is initiated later during 
the chronic phase may increase the possibility of virus recurrence and relapse upon 
discontinuation of therapy.  Indeed, our results demonstrating that patient T4, who 
exhibited viral recurrence, developed primarily a mono-functional immune response favour 
this hypothesis.  Furthermore, large scale studies demonstrated that the end of treatment 
response to PEG-IFN-α without ribavirin is approximately 56% when treatment is initiated 
late in the chronic phase (15) and 83% when treatment is initiated during the acute phase 
(62).  However, the SVR rate is much lower in individuals treated during the chronic phase 
reaching only 29% (15) versus 71% when treatment is started during the acute phase (62).   
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The reconstitution of poly-functional HCV-specific T cells after early IFN therapy 
argues in favour of early administration of interferon therapy.  Our results demonstrating 
that the recovered HCV-specific T cells bear the same phenotype and functional signatures 
as memory T cells generated upon spontaneous resolution suggest that this immune 
response may be protective upon re-exposure and further underscores the importance of 
early therapy administration.  Studies in the chimpanzee have demonstrated that prior 
resolution of one HCV infection can induce protection from chronic infection upon re-
exposure (51). Although such protective response is difficult to evaluate in humans, two 
reports have demonstrated that high-risk IDUs who have already resolved one HCV 
infection are less likely to be re-infected than individuals who are HCV-naïve, despite 
repeated high-risk exposures (21, 38). IDUs currently represent the main reservoir of HCV 
(2, 23). Although this group represents a major public health hazard they have limited 
access to treatment.  We demonstrate that treating this population at an early stage will 
eliminate the virus and minimize the risk of new transmissions, and we predict that the 
reconstitution of a poly-functional memory response may protect this population against 
new infections. 
In conclusion, our comprehensive phenotypic and functional characterization argues 
in favour of a more exhaustive multi-parametric signature analysis for HCV-specific cells 
at the earliest stages of infection. Our results suggest that poly-functionality rather than one 
single phenotypic or functional marker is more likely predictive of the outcome of acute 
HCV. Most importantly, we demonstrate that early administration of IFN therapy can 
rescue such functional signature and may potentially protect against re-infection upon re-
exposure in high-risk populations like IDUs. 
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2.1.8. Figure Legends 
 
Figure 1. Longitudinal phenotyping of virus-specific T cells during acute HCV. 
Representative longitudinal tetramer staining and phenotyping data from patient R1 with 
acute resolving HCV prior to and post detection of viraemia (A) and patient T4 with 
chronic evolution (B).  Tetramer frequency is represented as percent of CD3+CD8+ T cells.  
Black represents A2/HCV-1073 tetramer positive cells and red represents total CD3+CD8+ 
T cells in the same donor. Percentages of tetramer positive cells in each quadrant are 
shown.  (C) Summary of longitudinal phenotypic changes in CD127 and PD-1 expression 
on HCV-tetramer positive cells during acute HCV at the earliest and latest follow-up time 
point, prior to commencement of therapy.  Each symbol represents one HCV-tetramer as 
indicated in the legend. 
 
Figure 2. Spontaneous resolution of acute HCV infection is associated with up-
regulation of CD127 and Bcl-2 and early development of poly-functional HCV-specific 
T cells.  Representative data from patients R1 and R2 using A2/NS3-1073 and B8/NS3-
1395 tetramers, respectively. (A) Longitudinal expression of CD127 and intracellular Bcl-2 
in tetramer positive cells in patients R1 and R2, tetramer frequency is represented as 
percent of CD3+CD8+ T cells in the upper right quadrant.  Black represents tetramer 
positive cells and red represents total CD3+CD8+ T cells in the same donor, percentages of 
tetramer positive cells in each quadrant are shown. (B) CFSE proliferation of HCV specific 
T cells in absence or presence of the specific peptide, plots are gated on CD3+, CD8+ T 
cells, numbers in the upper left quadrant represent the percentage of proliferating (CFSE
lo
) 
tet+ cells.  (C) Longitudinal analysis of cytokine production and CD107a degranulation 
following specific peptide stimulation represented as percent specific expression of each 
individual cytokine/marker by viable, CD3+ CD8+ T cells. IFN-γ MFI is represented as a 
line graph. (*) indicates long-term follow-up experiments performed on a different date.  
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(D) Poly-functionality of HCV-specific T cells, gated on viable CD3+, CD8+, IFN-γ+ cells.  
Red represents 3 functions (IFN-γ+, IL-2+ and CD107a+), blue represents 2 functions 
(IFN-γ+ and CD107a+), green represents 2 functions (IFN-γ+ and IL-2+) and yellow 
represents one function (IFN-γ), numbers on the pie chart represent the percentage of each 
population. 
 
Figure 3. Chronically evolving acute HCV infection is associated with low expression 
of CD127 and Bcl-2 and effector functions.  Representative data from patients C1 using 
A2/NS3-1073 and A2/NS3-1406 tetramers (A) and patient C2 using B7/Core-41 tetramer 
(B).  Top panel depicts tetramer frequency relative to HCV-RNA viral load.  Middle panel 
represents longitudinal expression of CD127 and intracellular Bcl-2 in A2/NS3-1073 
tetramer positive cells in patient C1 (A) and B7/Core-41 tetramer positive cells in patient 
C2 (B); proliferation of HCV specific T cells in response to NS3-1073 peptide in patient C1 
or Core-41 peptide in patient C2 is depicted as bar graphs representing the percent of 
proliferating (CFSE
lo
) tet+ cells. Bottom panel represents longitudinal cytokine production 
and CD107a degranulation following stimulation with a mixture of NS3-1073 and NS3-
1406 peptides for patient C1 (A) or Core 41 peptide for patient C2 (B) represented as 
percent specific expression in viable, CD3+, CD8+ T cells.  
 
Figure 4. CD127 expression delineates a unique poly-functional T cell subset. CD3+ T 
cells from PBMCs of patient R2 at week 17 PDV were sorted into CD127
neg
 and CD127
hi
 
cells and tested for their proliferative capacity and cytokine production. (A) Pre and post 
sort purity of cells stained with B8/NS3-1395 tetramer, CD127 and Bcl-2. Black represents 
B8/NS3-1395 tetramer positive cells and red represents total CD3+CD8+ T cells, overall 
tetramer frequency is represented in the upper right quadrant, percentages of tetramer 
positive cells in each quadrant are shown. (B) CFSE proliferation of CD127
hi
 cells gated on 
CD3+CD8+ T cells, percentage of proliferating (CFSE
lo
) tet+ cells is represented in the 
upper left quadrant, the percentage of total cells in each quadrant is represented in the 
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bottom left quadrant.  Post sort CD127-neg cells were too few to perform this assay. (C) 
Cytokine production and CD107a degranulation of CD127
neg
 and CD127
hi
 cells stimulated 
with NS3-1395 peptide. Pie chart represents poly-functional analysis for CD127
hi
 cells, 
gated on viable CD3+, CD8+, IFN-γ+ cells.  Red represents 3 functions (IFN-γ+, IL-2+ and 
CD107a+), blue represents 2 functions (IFN-γ+ and CD107a+), green represents 2 
functions (IFN-γ+ and IL-2+) and yellow represents one function (IFN-γ), numbers on the 
pie chart represent the percentage of each population.  The frequency of IFN-γ producing 
cells in the CD127
neg
 population was too low to perform the poly-functional analysis. 
 
Figure 5. Early treatment with PEG-IFN-α rescues CD127+ Bcl-2+ HCV-specific T 
cells. Longitudinal phenotypic characterization and proliferative response of HCV tetramer 
positive T cells in Patient T1 using A1/NS3-1436 tetramer and treated between weeks 15 to 
27 (A), Patient T2 using B7/Core-41 tetramer and treated between weeks 32 and 54 (B) and 
Patient T3 using A2/NS3-1073 tetramer and treated between weeks 32 and 48 (C).  The 
grey shaded area represent the period of PEG-IFN-α therapy. Top panel depicts the 
respective tetramer(s) frequency relative to HCV RNA viral load.  Bottom panel represents 
the expression of CD127 and Bcl2 on tetramer positive cells and proliferation of HCV 
specific T cells in presence of their specific peptides depicted as bar graphs representing the 
percentage of proliferating (CFSE
lo
) tet+ cells.  
 
Figure 6. Early treatment with PEG-IFN-α rescues poly-functional HCV-specific T 
cells.  Longitudinal analysis of cytokine production, IFN-γ MFI and CD107a degranulation 
following specific peptide stimulation and poly-functionality in Patient T1 (A, B), Patient 
T2 (C, D) and Patient T3 (E, F).  The grey shaded areas represents the PEG-IFN-α 
administration period between weeks (15-27) in patient T1; (32-54) in patient T2 and (32-
48) in patient T3.  For poly-functionality, red represents 3 functions (IFN-γ+, IL-2+ and 
CD107a+), blue represents 2 functions (IFN-γ+ and CD107a+), green represents 2 
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functions (IFN-γ+ and IL-2+) and yellow represents on function (IFN-γ), numbers on the 
pie chart represent the percentage of each population.  Polyfucntional analysis was not 
performed before therapy when the frequency of IFN-γ producing cells was mostly lower 
than the cutoff threshold (0.02%) to accurately perform the poly-functionality analysis. 
 
Figure 7. Transient restoration of CD127 and Bcl-2 expression and limited poly-
functionality in HCV-specific T cells during therapy, followed by loss upon viral 
recurrence in patient T4. Longitudinal phenotypic characterization and proliferative 
response of A2/1073 tetramer positive T cells in patient T4. (A) Top panel represents the 
A2/1073 tetramer frequency relative to HCV RNA viral load.  Bottom panel represents the 
expression of CD127 and Bcl2 on tetramer positive cells, CFSE proliferation of HCV 
specific T cells in presence of NS3-1073 peptide is depicted as bar graphs representing the 
percentage of proliferating (CFSE
lo
) tet+ cells. (B) Longitudinal analysis of cytokine 
production, IFN-γ MFI and CD107a degranulation following NS3-1073 peptide 
stimulation. The grey shaded areas represent the period of administration of PEG-IFN-α 
therapy between weeks 21-36.  (C) Poly-functionality of HCV peptide-specific T cells in 
each patient.  Red represents 3 functions (IFN-γ+, IL-2+ and CD107a+), blue represents 2 
functions (IFN-γ+ and CD107a+), green represents 2 functions (IFN-γ+ and IL-2+) and 
yellow represents one function (IFN-γ), numbers on the pie chart represent the percentage 
of each population. The frequency of IFN-γ producing cells at some points prior to therapy 
was lower than the cutoff threshold (0.02%) to accurately perform the poly-functionality 
analysis.  
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Figure S1. Representative intracellular cytokine staining and CD107a degranulation 
from patient R1.  PBMCs were stimulated as described in Methods with either cognate 
peptide or DMSO control and gated on viable CD8+, CD3+ cells to analyze the expression 
of each cytokine/marker. (A) Representative expression of IFN-γ, IL-2, CD107a gated on 
viable CD8+, CD3+ T cells. (B, C) IFN-γ+ gates were then analyzed using PESTLE and 
SPICE softwares to determine the poly-functionality of the cells. 
 
Figure S2. CD127 expression delineates a unique poly-functional T cell subset in 
patient R1 with spontaneously resolved HCV infection. CD3+ T cells from PBMCs of 
patient R1 at week 57 PDV were sorted into CD127
neg
 and CD127
hi
 cells and tested for 
their proliferative capacity and cytokine production. (A) CFSE proliferation, sorted 
CD127
neg
 and CD127
hi
 cells, numbers in the upper left quadrant represent the percentage of 
proliferating (CFSE
lo
) tet+ cells, numbers in the bottom left quadrant represent the 
percentage of cells in each quadrant. (B) Summary of ICS and degranulation on CD127
neg
 
and CD127
hi
 cells. (C) Poly-functional analysis for CD127
neg
 and CD127
hi
 cells stimulated 
with NS3-1073 peptide, gated on viable CD3+, CD8+, IFN-γ+ cells.  Red represents 3 
functions (IFN-γ+, IL-2+ and CD107a+), blue represents 2 functions (IFN-γ+ and 
CD107a+), green represents 2 functions (IFN-γ+ and IL-2+) and yellow represents one 
function (IFN-γ), numbers on the pie chart represent the percentage of each population.  
The frequency of IFN-γ producing cells in CD127
neg
 cells was too low to perform poly-
functionality analysis. 
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Figure S3. IFN therapy does not alter the phenotype of non-HCV-specific CD8+ T 
cells. Control tetramer staining and phenotyping before, during and after IFN therapy is 
shown for: (A) Patient T1 with A2-CMVpp65 tetramer, (B) Patient T3 with B7/CMV-pp65 
tetramer, (C) Patient T4 with A2/CMV-pp65 tetramer and (D) Patient T4 with A2/Flu-M 
tetramer. Black represents expression tetramer positive cells and red represents expression 
on total CD3+ CD8+ T cells, in the same patient. Percentages of tetramer positive cells in 
each quadrant are shown. 
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2.1.9. Tables 
Table 1. Characteristics and demographics of acute HCV infected patients. 
 
 
Table 2. Patient’s HLA and tetramers used. 
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Table 3. Sequencing of HCV epitopes studied. 
        
Peptide sequence /autologous sequence          
(No. of clones) 
Patient 
ID 
Tetramer(s) 
used 
Early Late 
CINGVCWTV      CINGVCWTV      
--------- (13/13) --------- (8/9) A2/NS3-1073 
  --V------ (1/9) 
KLVALGINAV KLVALGINAV 
---S------ (7/9) 
---S------ 
(10/10) 
C2 
A2/NS3-1406 
---S-T---- (2/9)   
ATDALMTGY ATDALMTGY 
--------F (8/8) --------F (5/6) A1/NS3-1436 
  -----V--F (1/6) 
CINGVCWTV      CINGVCWTV      
T1 
A2/NS3-1073 
--------- (8/8) --------- (8/8) 
CINGVCWTV      CINGVCWTV      
-V------- (9/10) 
-V------- 
(10/10) 
T3 A2/NS3-1073 
-V-----A- (1/9)   
CINGVCWTV      CINGVCWTV      
T4 A2/NS3-1073 
--------- (13/13) 
--------- 
(10/10) 
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Supplementary table 1. Primer sequences used for amplification of HCV RNA for 
epitope sequencing. 
 
Epitope PCR Primer sequences (5’-3’) Reference 
Forward: GGCYTGCCCGTCTCYGCCCG 
Reverse: CGGCGCACSGGAATGACATCG First 
 
Forward: 
CGGCSTACKCCCARCAGACGMGAGGCC 
Reverse:  CCTCGTGACCARGTAAAGGTCC 
NS3-1073 
Nested 
  
Radziewicz H. et al., 
2007, J.Virol. 
81:2545-2553 
  Forward: CCATCACGTACTCCACCTACGGCAA 
NS3-1406 Reverse: GCGTGRTTGTCTCAATGGTGAAG 
And 
First 
 
NS3-1436 Forward: GCCCCATCCYAACATCGAGGAGGT 
  
Nested 
Reverse:  TTGCAGTCTATCACMGAGTCGAAG 
This manuscript 
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2.2.1. Abstract 
Early interferon-α (IFN-α) therapy against hepatitis C virus (HCV) rescues poly-
functional virus-specific memory CD8+ T cells but whether immune restoration is possible 
during late therapy remains controversial.  We compared immune restoration of HCV-
specific memory T cells in patients who cleared HCV infection spontaneously and 
following early or late IFN therapy.  Multi-functional, CD4+ and CD8+ memory T cells 
were detected in spontaneous resolvers and in individuals treated early following an acute 
infection.  In contrast, limited responses were detected in patients treated for chronic 
infection and phenotype of HCV-specific cells was influenced by autologous viral 
sequences.  Our data suggest that irreversible damage to the host immune system is 
associated with chronic HCV infection.   
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2.2.2. Introduction 
The majority of acute hepatitis C virus (HCV) infections become chronic with 
persistent viraemia and a chronic hepatitis (10).  Interferon alpha (IFN-α) based therapy is 
the only approved treatment for chronic HCV, its success rate ranges from 40-90% 
depending on the infecting genotype (8, 16).  Success of therapy is characterized by a 
sustained viral response (SVR) defined as undetectable HCV RNA in plasma at 6 months 
post termination of therapy.  SVR rates are greatly enhanced if therapy is started between 3 
and 6 months following acute HCV but the underlying mechanisms are not well understood 
(20, 21).  We have demonstrated that early interferon therapy for HCV can rescue long-
lived poly-functional CD8+ memory T cells (1).  Treatment induced memory T cells were 
identical in phenotype and function to natural memory T cells generated following 
spontaneously resolved infection.  They were CD127
hi
, Bcl-2
hi
, PD1
lo
 and poly-functional 
in nature (1).  However, whether immune restoration of HCV-specific CD4+ T cells also 
occurs has not been examined.  Furthermore, whether immune restoration is possible 
following late initiation of therapy during the chronic phase remains controversial.  Kamal 
et al. demonstrated that SVR is associated with a recovery in HCV specific CD4+ T-cell 
responses (11). In contrast, Barnes et al. demonstrated that induction of HCV-specific 
immunity during therapy does not correlate with outcome (2).  
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2.2.3. Methods, Results and Discussion 
The aim of this study was firstly to compare immune restoration of HCV-specific 
memory CD4+ and CD8+ T cell responses in patients who received early or late treatment. 
Secondly, we wanted to compare treatment induced/restored memory T cells to natural 
memory generated following spontaneously resolved acute HCV infection.  To address 
these issues, we performed cross-sectional comprehensive characterization of HCV-specific 
T cells using CFSE proliferation assays, intracellular staining for cytokines, cytotoxicity 
and poly-functionality analysis in a cohort of 23 patients who had successfully eliminated 
HCV-infection under different conditions.  Three subgroups were studied: a) patients who 
spontaneously resolved acute HCV infection without therapeutic intervention (SpR; n=5); 
b) patients who achieved SVR following IFN therapy initiated during acute HCV (A-SVR; 
n=5); and c) patients who achieved SVR following IFN therapy initiated during chronic 
HCV infection > 2 years post first detection of HCV-RNA (C-SVR; n=13). SpR and A-
SVR patients were recruited from an acute HCV cohort of intravenous drug users (IDUs) at 
St-Luc hospital of the CHUM as previously described (1, 5).  A-SVR patients received 12-
24 weeks of PEG-IFNα−2a (Pegasys) (Roche diagnostics, Welwyn Garden City, 
Hertfordshire, UK) (180 µg/week) and no ribavirin. C-SVR patients were recruited from 
patients with chronic HCV who had undergone successful treatment with the standard-of-
care therapy protocol (9) at the hepatology clinics of Toronto Western Hospital, Toronto, 
ON or St-Luc hospital of the CHUM. The infecting genotype had been mainly genotype 1, 
known to be the most resistant to IFN-α based therapy (15).  The distribution was: genotype 
1a (n=12); genotype 1b (n=6); genotype 3a (n=3) and undetermined genotype (n=2).  
Patients’ demographics and characteristics are listed in Supplementary Table1. 
The time point studied in this cross-sectional analysis was > 6 months post 
spontaneous resolution or end of antiviral therapy.  Immune responses were monitored 
using four peptide pools representing the NS3 and NS5B regions, the most 
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immunodominant regions of HCV (7, 12-14)  Each pool consisted of 42-49 overlapping 
peptides, 18 amino acids (AA)  long, overlapping by 11 AA as follows: Pool 1 (P1) NS3 
(1027-1339), Pool 2 (P2) NS3 (1340-1658), Pool 3 (P3) NS5B (2421-2716) and Pool 4 
(P4) NS5B (2717-3012).  Peptides were obtained from the Biodefense and Emerging 
Infections Research Resources Repository (BEI resources), Manassas, VA and matched 
with the infecting viral genotype in each patient (1a, 1b or 3a). All statistical analysis was 
performed by unpaired Student-t test using GraphPad Prism software version 5.02.  
Cross-sectional proliferative responses were first monitored using a CFSE dilution 
assay as previously described (1). CD4+ T cell proliferation was significantly higher in 
response to the P1 peptide pool in SpR and A-SVR patients  as compared to C-SVR (p< 
0.05, student t test) and in the A-SVR in response to the P4 peptide pool (Figure 1A).  
Furthermore, CD8+ T cell proliferative responses were consistently higher in A-SVR as 
compared to C-SVR in response to all peptide pools and in SpR in response to the P1 pool 
(Figure 1B).  There was no statistically significant difference between A-SVR and SpR 
patients. 
Next, we tested the functionality of HCV-specific CD4+ and CD8+ T cells by 
simultaneously examining the production of IFN-γ and IL-2, as well as cytotoxicity of 
CD8+ T cells using the surrogate CD107a degranulation assay (3) in response to the 4 HCV 
peptide pools as previously described (1).  Both IFN-γ and IL-2 responses by CD4+ T cells 
were consistently higher in response to several peptide pools in the A-SVRs as compared to 
the other two groups (Figure 2A, 2B).  Furthermore, in CD8+ T cells IFN-γ and CD107a 
responses were consistently higher in the SpR and A-SVR as compared to the C-SVR in 
response to most peptide pools (Figure 2C-E).  In contrast, very limited cytokine responses 
and/or CD107a responses were detected in the C-SVRs. The CD8+ T cells from the SpR 
group expressed the highest levels of CD107a, suggesting the cytotoxicity might be more 
crucial in spontaneous viral clearance as compared to treatment induced clearance. 
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We analyzed the poly-functionality of HCV-specific T cells. Functionality data was 
exported from FlowJo and poly-functionality analyzed using a mathematical algorithm for 
the calculation of the contribution of all possible combinations of mono-, dual- and tri-
functional cells.  Poly-functionality analysis was not performed for C-SVR patients as 
frequencies of cytokine producing cells were too low.  The CD4+ T cell responses in A-
SVR and SpR were primarily single IL-2 producers (Figure 3A), consistent with earlier 
reports documenting that loss of IL-2 production is one of the earliest functions lost upon 
dysfunction of virus-specific CD4+ T cells (6, 19, 22).  CD8+ T cells in both A-SVR and 
SpR were primarily CD107a single positive, indicating that cytotoxicity was crucial in both 
responses. However, in dual function cells, A-SVR were more biased toward IFNγ+, IL-2+ 
while SpR were more IFNγ+, CD107a+ (Figure 3B).  These results suggest that despite an 
overall similar memory T cell profile, minor functional difference may exist between 
natural T cell memory and treatment induced memory.  It is also possible that IFN therapy, 
by virtue of its immune-modulatory role, can influence the functional profile of virus-
specific memory cells. 
To confirm that indeed there was no short-lived recovery in HCV-specific memory 
T cells in the C-SVR group, we examined HCV-specific immune responses longitudinally 
in 8 of the C-SVR patients for whom longitudinal samples were available in an IFN-γ 
ELISpot assay using a panel of 12 peptide pools spanning the entire HCV polyprotein.  
Three time points were examined:  baseline, 5-6 months post start of therapy and at > 6 
months post termination of therapy.  As previously reported (2, 17), we did not observe any 
de novo HCV-specific T cell responses and no statistically significant enhancement in any 
of the responses that existed at baseline (Supplementary Figure S1).  
Finally, to confirm that HCV-specific responses were limited or severely defective 
from the start in chronically infected patients, we screened C-SVRs prior to starting 
interferon therapy with a panel of 10 MHC class I tetramers corresponding to the most 
dominant HCV-class I epitopes (Supplementary Table S2).  No responses were detected 
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except in 1/13 patients (patient C-SVR-5), who reacted to an A1/NS3-1406 tetramer at a 
frequency of 0.018% of CD8+ T cells (Figure 4A).  Despite the fact that this patient was 
chronically infected for over 2 years with a viral load of 12 x 10
6
 IU/ml, HCV tetramer-
specific cells were CD127
hi
, PD1
lo
 (Figure 4A) consistent with a memory phenotype only 
previously observed in spontaneously resolved individuals.  Furthermore, these tetramer 
positive cells proliferated efficiently at 89% of tetramer+ cells (Figure 4B) and produced 
cytokines in response to the specific peptide epitope (Figure 4C).  In order to understand 
this confusing result, we sequenced the autologous virus circulating in this patient, 8/8 
molecular clones sequences contained a (Y ⇒ F) change in residue 9.  When the 
recognition of the tetramer peptide sequence and the autologous viral sequence were 
compared over several fold dilution in an ELISpot assay, we observed decreased 
recognition of the autologous viral sequence (Figure 4C).  These results suggest that this 
epitope probably underwent mutation at an earlier time point to the current autologous 
sequence that is recognized less efficiently.  This diminished recognition most likely 
prevented exhaustion of T cells specific for the original peptide and facilitated their 
transformation or preservation into long-lived memory T cells. This is consistent with 
recent results demonstrating that expression of the exhaustion marker PD-1 is likely 
influenced by the degree of recognition of the autologous viral sequence (18) and might be 
lost following viral escape mutations (4).  
Our results suggest that both HCV-specific CD4+ and CD8+ T cells become 
persistently defective with prolonged infection.  Nevertheless, there is a narrow window of 
time early during the acute phase where some functional aspects of the HCV-specific T cell 
response might be rescued.  Early therapeutic intervention during this period and 
subsequent viral clearance seems to prevent T cell exhaustion as is seen with chronic 
hepatitis C thereby allowing their development into long-lived memory T cells.  Similarly, 
variations in viral sequences leading to loss or diminished recognition of the autologous 
viral sequence by T cells, decrease T cell exhaustion and permit such T cells to develop 
into a functional memory T cell pool.  
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Our data suggest that adaptive immunity may play an active role in clearance of 
HCV and can be recovered when IFN therapy is initiated early but irreversible damage to 
the host immune system occurs with chronic HCV infection.  The question of whether 
immune restoration during antiviral treatment of acute hepatitis C is a cause or effect of 
enhanced response to therapy remains unresolved.  We favour the hypothesis that enhanced 
immune responses may play a role in instigating viral clearance, but that the reconstitution 
of memory T cells is more likely an effect of that viral clearance. Our data also suggest that 
there could be minor differences between natural memory and therapy-reconstituted 
memory T cells and whether they would have the same protective capacity upon re-
exposure to the virus requires further investigation. 
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2.2.6. Figure Legends 
 
Figure 1. Limited proliferation of HCV-specific CD4+ and CD8+ T cells in HCV-
patients achieving SVR following late therapy (C-SVR) as compared to patients who 
resolved following early IFN therapy (A-SVR) or who resolved spontaneously (SpR). 
Cumulative data from CFSE proliferation assays performed on the different patients groups 
represented as stimulation indices (SI) in response to different HCV peptide pools in (A) 
CD4+ and (B) CD8+ T cells. (* p<0.05, Student-t test) 
 
Figure 2. Higher IFN-γ and CD107a responses in CD8+ T cells and higher IL-2 
responses in CD4+ T cells in SpR and A-SVRs as compared to C-SVR. Cumulative data 
from the different patients groups for IFN-γ, IL-2 and CD107a expression in a standard 
intracellular staining for cytokines (ICS) assay in response to stimulation with different 
HCV peptide pools. (* p<0.05, ** p<0.01, Student-t test) 
 
Figure 3. Minor differences in poly-functionality profiles between SpR and A-SVRs. 
Poly-functionality data gated on viable, CD3+, CD4+T cells (A) or CD8+ T cells (B). 
There was no significant difference in the percentages of poly-functional cells between SpR 
and A-SVRs.  For C-SVRs the individual production of cytokines was too low to analyze 
poly-functionality. 
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Figure 4. Virus-specific memory CD8+ T cells with long-lived memory phenotype in 
chronic HCV have limited functionality against the autologous viral sequence. 13 
chronic HCV patients were screened using a panel of 10 MHC class I tetramers, patient C-
SVR-5 was the only patient where HCV-specific tetramer+ CD8+ T cells were detected 
using A1/NS3-1436 tetramer. (A) Detection and phenotyping (PD-1, CD127 expression) of 
A1/NS3-1436 tetramer reactive T cells.  Cells are gated on viable, CD3+, CD8+ T cells. 
Black represents tetramer positive cells and grey represents total CD3+ CD8+ T cells in the 
same donor, percentages of tetramer positive cells in each quadrant are shown. (B) 
Proliferation of A1/NS3-1436 tetramer+ cells in response to the reference peptide in a 
CFSE dilution assay. (C) Dose response for the reference tetramer peptide sequence versus 
the autolgous virus sequence for the NS3-1436 epitope in patient C-5 using IFN-γ ELISpot 
assay. Results are represented as specific spot forming cells (SFC)/ 10
6
 PBMCs.  
 
Figure S1. No restoration of immune responses against HCV in patients who resolved 
after receiving IFN-α therapy in the chronic phase (C-SVRs). Results are represented as 
the mean of C-SVR patients’ responses (n=8) in an IFN-γ ELISpot assay against the 
indicated HCV peptide pools. Each pool consisted of 39-50 overlapping peptides 
representing the entire HCV polyprotein.  Peptides are 18 AA long, overlapping by 11 AA 
(Biodefense and Emerging Infections Research Resources Repository (BEI resources)). No 
significant difference was observed in the responses between the different time points 
tested. The dashed line represents the positivity threshold (50 SFC/ 10
6
 PBMCs).  
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2.2.7. Tables 
Supplementary Table S1. Demographic characteristics of patients with HCV 
 
A. Patients receiving IFN therapy during the chronic phase (C-SVR) 
 
Gender Age HCV genotype 
M/F Median 
(Range) 
1a 1b 3a ND 
9/4 47 
(34-61) 
8 5   
 
 
     
B. Patients receiving IFN therapy during the acute phase (A-SVR) 
 
Gender Age HCV genotype 
M/F Median 
(Range) 
1a 1b 3a ND 
5/0 34 
(30-47) 
3 1 1  
 
 
     
C. Patients who spontaneously resolved from hepatitis C (SpR) 
 
Gender Age HCV genotype 
M/F Median 
(Range) 
1a 1b 3a ND 
4/1 32 
(23-46) 
1  2 2 
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Supplementary Table S2. MHC class I tetramers used in screening HCV-specific 
CD8+ T-cell responses in chronic patients prior to start of therapy 
 
Restricting HLA 
Allelle 
HCV Protein AA Peptide sequence 
A1 NS3 1436-1444 ATDALMTGY 
    
A2 Core 131-140 ADLMGYIPLV 
  E2 614-622 RLWHYPCTV 
  NS5B 2594-2603  ALYDVVTKL 
  NS3 1073-1081  CINGVCWTV  
  NS3 1406-1415  KLVALGINAV  
  NS4b 1807-1816  LLFNILGGWV  
    
A3 E2 630-639 RMYVGGVEHR 
    
B7 Core 41-49 GPRLGVRAT 
    
B8 NS3 1395-1403 HSKKKCDEL 
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Results from the longitudinal study that we performed using MHC class I tetramers 
(Article 2.1) enabled us to define the phenotypic and functional markers of HCV-specific 
CD8+ T cells associated with patients clearing HCV spontaneously, thus considered as 
determinants of a successful adaptive immune response against HCV. We demonstrate that 
spontaneous resolution is associated with early emergence of poly-functional memory T 
cells that up-regulate CD127 and Bcl-2. This suggests that they represent transitional 
effector memory T cells (TTEM). Moreover, we were able to demonstrate that early 
therapeutic intervention during acute HCV-infection can rescue poly-functional memory T 
cells with similar phenotypic and functional characteristics as observed following 
spontaneous resolution. Results from our cross-sectional study using peptide pools (Article 
2.2) confirmed and extended our conclusions for CD8+ T cells; CD8+ T cells in 
spontaneous resolvers and SVRs after early therapy (A-SVR) consistently displayed higher 
functions than chronic SVRs (C-SVR). Similar results were observed for CD4+ T cells. 
The possibility that the longitudinal changes observed in the CD8+ T-cell responses 
in our first study were due to viral escape was ruled out. However, one chronically infected 
individual in the cross-sectional study who had HCV-tetramer-specific CD8+ T cells that 
were CD127
hi
 PD1
lo
 did show one amino acid difference between the autologous and the 
tetramer peptides that led to a diminished recognition of the autologous viral sequence. This 
could be a possible reason preventing exhaustion and preservation of memory T cells. 
Collectively, our results demonstrate restoration of efficient HCV-specific immune 
responses when interferon therapy is initiated early during the acute phase. This is 
demonstrated by the rescue of functional HCV-specific T cells similar in phenotype and 
functionality to those observed in spontaneously resolved individuals, and suggests that 
they may play an active role in response to therapy. However, such responses were not 
restored following late therapy suggesting that irreversible damage to the host’s defence 
system precipitates with HCV infection as it proceeds towards chronicity preventing it from 
playing an active role with late initiation of therapy.   
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3.1. Successful HCV-specific CD8+ T cells in spontaneously resolved 
infections are poly-functional memory T cells 
We performed comprehensive longitudinal multi-parametric phenotypic and 
functional characterization of the HCV-specific immune response during clearly defined 
acute infection in a unique cohort of IDUs with differential outcomes of acute-HCV 
infection, including spontaneous resolution and proceeding to chronicity. We used MHC 
class I tetramers to detect the responses of HCV-specific CD8+ T cells targeting defined 
immunodominant epitopes (Article 2.1). We demonstrate that spontaneous resolution is 
specifically associated with early emergence of memory CD8+ T cells, defined by the up-
regulation of CD127 on cells and intracellular content of the anti-apoptotic molecule Bcl-2, 
a common characteristic of long-lived memory T cells [293].  Despite a measurable 
immune response detected at the early time points, HCV-specific T cells failed to 
upregulate CD127 and Bcl-2 expression in individuals who developed persistent viraemia 
and eventually disappeared from peripheral blood. In agreement with previous reports we 
demonstrate that PD-1 expression does not correlate with the outcome of acute HCV [197, 
198], except at the highest viral loads. 
These cells are poly-functional; defined as the capacity to simultaneously produce 
more than one cytokine, in addition to cytotoxic and proliferative capacity [294, 295].  
Such poly-functional T cells were recently correlated with control of HIV infection [296, 
297], response to HIV vaccines [290, 298] and anti-retroviral therapy [291].  We 
established that these poly-functional memory T cells in the context of HCV are: CD27+, 
CD28+, CCR7-, CD45RA-, CD127+, Bcl-2+.  A similar memory T cell subset at a 
transitional or early maturation stage (CD27+, CD28+, CD127+) with a short replicative 
history and strong telomerase activity was recently described [299].   
In this context, we demonstrate that CD127 expression distinguishes a unique subset 
of HCV-specific memory T cells bearing the phenotypic signature of effector memory T 
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(TEM) cells (CCR7-CD45RA-) and yet bearing the functional signatures of both central 
memory T cells (TCM) (rapid proliferation, high IL-2 production) and TEM (high IFN-γ 
production and cytotoxic potential). We propose that this poly-functional T-cell subset 
represents transitional effector memory T cells (TTEM) that are long-lived but also constitute 
the first responders upon antigen encounter in the periphery.  Although this T-cell subset is 
distinguished primarily by CD127 expression, it is unlikely that CD127 alone can be used 
as a marker of such polyfunctional memory T cells or to predict the outcome of HCV 
infection or therapy.  Such simplistic models of defining maturation of virus-specific T 
cells and their functional capacity are no longer sufficient but a comprehensive systematic 
phenotypic, functional and even genomic profiling will be essential.   
3.2. Similar profile of early-treatment induced memory T cells and 
normal memory T cells 
PEG-IFN-α therapy for HCV is most effective when initiated early during the acute 
phase [243, 300, 301] but the potential contribution of adaptive cellular immunity in this 
enhanced response is controversial with several reports demonstrating a decline in the 
immune response during therapy [58-60, 288].  In the present study, we do not observe any 
significant change in the frequency of HCV-specific T cells detected by tetramers during 
therapy in acute HCV patients nor by ELISpot during therapy initiated in chronic patients.  
Although we did observe a gradual decline over time, HCV-specific T cells remained 
detectable for up to 1.5 years of follow-up.  Such differences between the various studies 
might be due to the therapeutic regimen or the nature of the dominant immune response 
generated in each patient and how accurately it matches the autolgous virus sequence. 
Our results from the longitudinal study (Article 2.1) demonstrate that early 
therapeutic intervention can rescue a poly-functional immune response with the same 
phenotypic and functional characteristics as memory T cells induced following spontaneous 
resolution.  However, it remains unclear if such reconstituted response is the cause or the 
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effect of enhanced virus clearance during early therapy.  We favour the hypothesis that re-
constitution of a poly-functional immune response is a consequence of virus elimination 
and prevention of continued T cell exhaustion similar to acute resolving HCV and other 
viral infections [293].  It is likely that there is a limited window of time where IFN therapy 
can rescue such a poly-functional response before HCV-specific T cells become severely 
exhausted and eliminated from the circulation.  In agreement with this hypothesis, we 
demonstrate that HCV-specific cells eventually become undetectable in patients who 
declined HCV therapy.  Similarly, several reports in the literature have demonstrated that 
HCV-specific T cells are mostly undetectable in the peripheral blood of chronically 
infected individuals, mostly localized in the liver or targeting epitopes that underwent 
escape mutations, thus preventing exhaustion of the specific T cells.  
Longevity is one of the unique characteristics of memory T cells.  HCV-specific 
memory T cells were detected in spontaneously resolved infections for up to 20 years in 
absence of any detectable viraemia [302].  Similarly, in the longitudinal study (Article 2.1), 
we demonstrate that although HCV-specific memory T cells declined over time, they 
remained detectable at a reasonable frequency for up to one year following spontaneous 
resolution or sustained viral response to interferon therapy.  All patients were tested at 
multiple time points by the most sensitive PCR assays (sensitivity 50 IU/ml plasma) and 
were consistently negative, suggesting that HCV-specific T-cell memory is antigen 
independent and that establishment of a long-lived memory response is due to successful 
viral elimination and prevention of persistent T-cell activation and exhaustion.  
Nevertheless, it is still possible that very low level residual virus or intermittent viral 
replication [303] contribute to long-term maintenance of virus-specific memory T cell 
populations.  
In the second part of our study (Article 2.2), we performed cross-sectional 
comprehensive phenotypic and functional characterization of both HCV-specific CD4+ and 
CD8+ T cells in a cohort of patients who have successfully eliminated HCV-infection 
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under different conditions.  Three subgroups were identified: patients who spontaneously 
resolved acute HCV infection without therapeutic intervention (SpR), patients who 
achieved SVR following IFN therapy initiated during acute HCV (A-SVR) and patients 
who achieved SVR following IFN therapy initiated during chronic HCV infection more 
than 2 years post first detection of HCV-RNA and diagnosis of chronic infection (C-SVR). 
The proliferation and functionality were assessed in response to peptide pools 
corresponding to immunodominant regions representing a third of the entire HCV genome.    
Our results show that CD8+ T-cell proliferative responses were consistently higher 
in A-SVR as compared to C-SVR in response to all peptide pools. CD8+ T cells in the SpR 
and A-SVR displayed consistently higher production and expression of functional markers 
(IFN-γ and CD107a) as compared to the C-SVR. Polyfunctionality analysis showed that 
CD8+ T cells in both A-SVR and SpR were primarily CD107a single positive, indicating 
that cytotoxicity was crucial in both responses. However, in dual function cells, A-SVR 
were more biased toward IFNγ+, IL-2+ while SpR were more IFNγ+, CD107a+. These 
results suggest that despite an overall similar memory T-cell profile, minor functional 
difference may exist between natural T cell memory and treatment induced memory.  It is 
also possible that IFN therapy, by virtue of its immune-modulatory role, can influence the 
functional profile of virus-specific memory cells. 
We also characterized CD4+ T-cell help, being the most important factor 
contributing to the induction of poly-functional T cells and establishment of T-cell memory 
[293].  CD4+ T cells play an essential role in establishment and maintenance of CD8+ 
memory T cells in various models of murine and human infections [304-306].  In particular, 
acute HCV infections that progress to chronicity have been linked to the inability to sustain 
a CD4+ helper T-cell response [158, 114, 135].  Depletion studies in the chimpanzee model 
have demonstrated that loss of CD4+ T cells results in loss of function and a decline in 
HCV-specific CD8+ T cells and enhanced emergence of escape mutations in targeted CTL 
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epitopes [157].  The role of CD4+ T-cell help and the mechanisms of cross talk between 
CD4+ and CD8+ T cells during the memory phase, still remain to be elucidated [307, 308].  
Indeed, we observed significantly higher proliferation in the SpR and A-SVR 
groups as compared to C-SVR.  Both IFN-γ and IL-2 responses by CD4+ T cells were 
consistently higher in the A-SVRs as compared to the other two groups. In order to assess 
the contribution of each cytokine to the total memory immune response and to assess poly-
functionality of HCV-specific memory T cells generated in the three groups of patients 
studied, we analyzed the poly-functionality of HCV-specific T cells.  Interestingly, CD4+ 
T-cell responses in A-SVR and SpR were primarily single IL-2 producers, consistent with 
earlier reports documenting that loss of IL-2 production is one of the earliest functions lost 
upon dysfunction of virus-specific CD4+ T cells [192, 309, 310].   
3.3. Role of viral-sequence variation in memory T-cell preservation 
We demonstrate a major change in the immune response following therapy during 
the acute phase while the circulating viral population remains unchanged (Article 2.1), 
thereby excluding a potential influence for viral escape on the immune response to the 
epitopes studied.  However, we did not perform a detailed analysis of viral escape in these 
patients and it remains an important mechanism for HCV immune evasion.  It is still 
possible that viral escape did occur in other regions and may have contributed to viral 
persistence.  Furthermore, the increased poly-functionality of virus-specific T cells may 
induce new selection pressure and trigger mutational escape.  A more comprehensive 
analysis of poly-functionality in relation to full length viral sequencing is essential to 
elucidate this point.  
Interestingly, one persistently infected patient did show a population of HCV 
tetramer-specific cells that were CD127
hi
 PD1
lo
 consistent with a memory phenotype 
observed in spontaneously resolved individuals, despite the fact that this patient was 
chronically infected for over 2 years and with a high viral load (Article 2.2). Furthermore, 
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these tetramer positive cells proliferated efficiently and produced cytokines in response to 
the specific peptide epitope. By sequencing the autologous virus circulating in this patient, 
a change in one of the anchor residues was observed. Interestingly, we observed decreased 
recognition of the autologous viral sequence. These results suggest that this epitope 
probably underwent mutation at an earlier time point to the current autologous sequence 
that is recognized less efficiently.  This diminished recognition most likely prevented 
exhaustion of T cells specific for the original peptide and their transformation into long-
lived memory T cells.  This is consistent with recent results demonstrating that expression 
of the exhaustion marker PD-1 is likely influenced by the degree of recognition of the 
autologous viral sequence [311].  
Our results demonstrate the reconstitution of poly-functional HCV-specific T cells 
after early IFN therapy, which argues in favour of early administration of interferon 
therapy.  These recovered HCV-specific T cells bearing the same phenotype and functional 
signatures as memory T cells generated upon spontaneous resolution suggest that this 
immune response may be protective upon re-exposure, and further underscore the 
importance of early therapy administration. Studies in the chimpanzee have demonstrated 
that prior resolution of one HCV infection can induce protection from chronic infection 
upon re-exposure [312]. Although such protective response is difficult to evaluate in 
humans, two reports have demonstrated that high risk IDUs who have already resolved one 
HCV infection are less likely to be re-infected than individuals who are HCV-naïve, despite 
repeated high risk exposures [173, 313]. We demonstrate that treating at an early stage will 
eliminate the virus in IDUs and minimize the risk of new transmissions from this 
population which is the main reservoir of HCV [314, 315]. Further, we predict that the 
reconstitution of a poly-functional memory response may protect this population against 
new infections. 
Our results suggest, as well, that HCV-specific CD4+ and CD8+ T cells become 
persistently defective with prolonged infection.  Nevertheless, there is a narrow window of 
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time early in the acute phase where some functional aspects of the HCV-specific T-cell 
response might be rescued.  Early therapeutic intervention during this period and 
subsequent viral clearance prevents T-cell exhaustion and allows their development into 
long-lived memory T cells.  Similarly, variations in viral sequences leading to loss or 
diminished recognition of the autologous viral sequence by T cells decrease T-cell 
exhaustion. Although such T cells may maintain certain antiviral functions and provide 
partial control of viral replication, they can develop into a ‘non-exhausted’ memory T cell 
pool. 
 Conclusion  
In conclusion, our comprehensive phenotypic and functional characterization argues 
in favour of a more exhaustive multi-parametric signature analysis for HCV-specific T cells 
at the earliest stages of infection. Our results suggest that poly-functionality rather than one 
single phenotypic or functional marker is more likely predictive of the outcome of acute 
HCV infection.  
Most importantly, we demonstrate that early administration of IFN therapy during 
the acute phase can rescue such functional signature of HCV-specific adaptive immune 
responses which we consider an effective adaptive immune response. These responses were 
similar to those responses observed in individuals who spontaneously cleared HCV. This 
restoration suggests that the HCV-specific adaptive immune responses might play an active 
role in the success of therapy and the achievement of a sustained virological response 
(SVR) when initiated early during the acute phase. However, such responses were not 
restored following late therapy during the chronic phase, which might be due to irreversible 
damage to the host immune system that precipitates with chronic HCV infection.     
The question of whether immune restoration during treatment in the acute phase is a 
cause or effect of enhanced response to therapy remains unresolved.  We favour the 
hypothesis that enhanced immune responses may play a role in enhanced viral clearance, 
but the reconstitution of memory T cells is likely an effect of viral clearance that abrogates 
viral pressure which might hinder the establishment of such a long-lived memory pool.  
Nevertheless, such reconstituted memory T cells may play a more central role in preventing 
viral recurrence upon discontinuation of therapy.  Our data also suggest that there could be 
minor differences between natural memory and therapy-reconstituted memory T cells and 
whether they would have the same protective capacity against re-infection upon re-
exposure to the virus, especially in high risk populations like IDUs, remains elusive. 
Taken together, our data suggest that the timing of initiation of IFN-α therapy 
against HCV is a critical factor in the restoration of an effective HCV-specific immune 
response that might play an effective role in viral clearance. 
 Perspectives  
We demonstrated the inability of late initiation of IFN therapy during the chronic 
phase to restore effective HCV-specific immune responses, and thus its failure to play an 
active role in the success of therapy. It is thus essential to study other factors that might 
play an important role in the different outcomes of acute infection and the achievement of 
SVR to therapy during the acute phase, and more important during the chronic phase. In 
particular, to define what might be directly influencing the outcome of acute HCV infection 
and response to therapy. An attractive approach is testing the impact on different 
determinants of the immune system of different regions sequenced from clinical isolates 
obtained from patients of differential outcomes of acute infection and responses to therapy. 
Defining these viral determinants is essential in understanding the mechanisms underlying 
resistance to the available current treatment and would help in the development of novel 
therapeutic regimens. 
To pursuit our characterization of a successful HCV-specific immune response, it is 
essential to define molecular and/or functional signature of what constitutes a 
successful/protective immune response against HCV. This information is critical to assess 
the efficiency of new vaccines or therapeutic strategies aimed at reconstituting an efficient 
immune response. Such signatures could also be used to predict the outcome of HCV 
infection and the need for early therapeutic intervention.  It is essential to use an integrated 
functional genomics and protein profiling approach coupled with phenotypic analysis to 
define signatures of a successful immune response against HCV. Furthermore, it is essential 
to examine and compare at the genetic and molecular level the characteristics of HCV-
specific effector and memory T cells early during the acute phase and following HCV-
spontaneous or treatment induced clearance. This will help in determining whether 
immunological memory reconstituted following therapy is equivalent to spontaneous 
clearance induced memory. It will also help in verifying whether both types of memory 
cells would maintain the same functional profile over long periods of time and convey the 
same level of protection upon re-infection in populations at high risk such as IDUs. 
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